

UC Berkeley

UC Berkeley Previously Published Works

Title

A lncRNA fine tunes the dynamics of a cell state transition involving Lin28, let-7 and de novo DNA methylation

Permalink

<https://escholarship.org/uc/item/0d78r4dv>

Authors

Li, Meng Amy
Amaral, Paulo P
Cheung, Priscilla
et al.

Publication Date

2017

DOI

10.7554/elife.23468

Peer reviewed

A lncRNA fine tunes the dynamics of a cell state transition involving *Lin28*, *let-7* and *de novo* DNA methylation

Meng Amy Li^{1,2*†}, Paulo P Amaral³, Priscilla Cheung², Jan H Bergmann⁴, Masaki Kinoshita¹, Tüzer Kalkan¹, Meryem Ralsler¹, Sam Robson^{3‡}, Ferdinand von Meyenn⁵, Maike Paramor¹, Fengtang Yang⁶, Caifu Chen⁷, Jennifer Nichols¹, David L Spector⁴, Tony Kouzarides³, Lin He^{2*}, Austin Smith^{1,8*}

¹Wellcome Trust - Medical Research Council Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom; ²Division of Cellular and Developmental Biology, Department of Molecular and Cellular Biology, University of California Berkeley, Berkeley, United States; ³The Gurdon Institute, University of Cambridge, Cambridge, United Kingdom; ⁴Cold Spring Harbor Laboratory, Cold Spring Harbor, United States; ⁵Babraham Institute, Cambridge, United Kingdom; ⁶Wellcome Trust Sanger Institute, Hinxton, United Kingdom; ⁷Integrated DNA Technologies, Redwood, United States; ⁸Department of Biochemistry, University of Cambridge, Cambridge, United Kingdom

*For correspondence: ml440@cam.ac.uk (MAL); lhe@berkeley.edu (LH); austin.smith@cscr.cam.ac.uk (AS)

Present address: [†]Wellcome Trust- Medical Research Council Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom; [‡]Bioinformatics Group, School of Pharmacy & Biomedical Science, University of Portsmouth, Portsmouth, United Kingdom

Competing interests: The authors declare that no competing interests exist.

Funding: See page 18

Received: 19 November 2016

Accepted: 24 July 2017

Published: 18 August 2017

Reviewing editor: Martin Pera, University of Melbourne, Australia

© Copyright Li et al. This article is distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use and redistribution provided that the original author and source are credited.

Abstract Execution of pluripotency requires progression from the naïve status represented by mouse embryonic stem cells (ESCs) to a state capacitated for lineage specification. This transition is coordinated at multiple levels. Non-coding RNAs may contribute to this regulatory orchestra. We identified a rodent-specific long non-coding RNA (lncRNA) *linc1281*, hereafter *Ephemeron* (*Eprn*), that modulates the dynamics of exit from naïve pluripotency. *Eprn* deletion delays the extinction of ESC identity, an effect associated with perduring *Nanog* expression. In the absence of *Eprn*, *Lin28a* expression is reduced which results in persistence of *let-7* microRNAs, and the up-regulation of *de novo* methyltransferases *Dnmt3a/b* is delayed. *Dnmt3a/b* deletion retards ES cell transition, correlating with delayed *Nanog* promoter methylation and phenocopying loss of *Eprn* or *Lin28a*. The connection from lncRNA to miRNA and DNA methylation facilitates the acute extinction of naïve pluripotency, a pre-requisite for rapid progression from preimplantation epiblast to gastrulation in rodents. *Eprn* illustrates how lncRNAs may introduce species-specific network modulations.

DOI: [10.7554/eLife.23468.001](https://doi.org/10.7554/eLife.23468.001)

Introduction

Mouse embryonic stem cells (ESCs), *in vitro* counterparts of the pre-implantation epiblast, exhibit dual properties of self-renewal and differentiation (Boroviak et al., 2015; Bradley et al., 1984; Evans and Kaufman, 1981; Martin, 1981). These properties make them an attractive system for investigating cell fate decision making. In the embryo, spatially and temporally coordinated signals direct the rapid and continuous transition of the epiblast towards lineage specification (Acampora et al., 2016; Smith, 2017). In contrast, ESCs can be suspended in a ground state of pluripotency, where self-renewal is decoupled from lineage specification, using two inhibitors (2i) of glycogen synthase kinase 3 (GSK3) and mitogen-activated protein kinase kinase (MEK1/2), along with the cytokine leukaemia inhibitory factor (LIF) (Ying et al., 2008). Therefore, ESCs provides a unique

experimental system to explore the principles and molecular players underlying the developmental progression of pluripotency (Kalkan and Smith, 2014).

While it is increasingly clear that the ESC state is maintained by a core network of transcription factors (Chen et al., 2008; Dunn et al., 2014; Ivanova et al., 2006), less is known about how cells progress from this state to lineage specification (Buecker et al., 2014; Kalkan and Smith, 2014; Smith, 2017). Loss-of-function screens have highlighted a multi-layered machinery that dismantles the naïve state transcription factor network (Betschinger et al., 2013; Leeb et al., 2014). The latency period for transition depends on the clearance kinetics of network components (Dunn et al., 2014). The orchestration of multiple regulators thus ensures rapid and complete dissolution of this core network and consequent timely extinction of ESC identity upon 2i withdrawal (Kalkan and Smith, 2014).

In addition to protein coding genes, accumulating evidence suggests that non-coding RNAs can contribute to the regulation of cell fate transitions. Within this class, long non-coding RNAs (lncRNAs) comprise a large fraction of the transcriptome in diverse cell types and exhibit specific spatio-temporal expression (Carninci et al., 2005; Guttman et al., 2009; Necselea et al., 2014). The genomic distribution of lncRNAs is non-random (Luo et al., 2016). A subclass of lncRNAs are divergently transcribed from neighbouring genes and thought to regulate proximal gene expression in cis, either due to the process of transcription (Ebisuya et al., 2008; Engreitz et al., 2016; Martens et al., 2004) or through local lncRNA-protein interactions that recruit regulatory complexes (Lai et al., 2013; Lee, 2012; Luo et al., 2016; Nagano et al., 2008). However, the functions and mode of action of the vast majority of lncRNAs remain unknown and require case-by-case experimental determination. In mouse ESCs, knockdowns of a number of lncRNAs have been reported to exert effects on the transcriptome (Bergmann et al., 2015; Dinger et al., 2008; Guttman et al., 2011; Lin et al., 2014; Sheik Mohamed et al., 2010) and in some cases impair self-renewal (Lin et al., 2014; Luo et al., 2016; Savić et al., 2014).

We investigated the potential involvement of lncRNAs in transition from the naïve ESC state and identified a dynamically regulated lncRNA (linc1281) that we named *Ephemeron* (*Eprn*). We present functional evaluation of *Eprn* and delineation of a downstream genetic interaction network, which is an additional component of the regulatory machinery driving the irreversible and rapid progression from naïve pluripotency in rodent.

Results

Identification of lncRNAs associated with transition from naïve pluripotency

Post-implantation epiblast derived stem cells (EpiSCs) represent a primed state of pluripotency developmentally downstream of naïve state ESCs (Brons et al., 2007; Nichols and Smith, 2009; Tesar et al., 2007). To identify lncRNA candidates with a possible role in ESC transition, we analysed in silico the effect of genetic perturbation on expression of ESC and EpiSC states based on published data. We first selected genes that are over ten-fold differentially enriched in ESCs (182 genes) and EpiSCs (131 genes) relative to each other as molecular signatures to represent these two states (Tesar et al., 2007). Using published data, we investigated the impact on these two signature sets when individual lncRNAs (147 in total) and known protein coding regulators (40 in total) were knocked down in ESCs grown in LIF/serum (Guttman et al., 2011) (Figure 1A, Figure 1—source data 1). Serum culture supports a heterogeneous mixture of naïve, primed and intermediate cells (Chambers et al., 2007; Kolodziejczyk et al., 2015; Marks et al., 2012). Therefore, analysis in this condition could potentially reveal regulators of the ESC and EpiSC states. The effect of each gene knockdown was plotted based on the percentage of genes significantly altered within ESC and EpiSC signature sets (FDR < 0.05 and fold change >2 or <0.5 over negative control defined by the original study). We validated the approach by analysing the knockdown effects of known ESC self-renewal regulators. As predicted, depletion of factors that maintain the ESC state, such as Stat3, Esrrb, Sox2 and Klf4, led to a decrease in ESC and increase in EpiSC signature (Figure 1A), while knockdown of Oct4 gave rise to a decrease in both ESC and EpiSC signatures, consistent with its requirement in both states (Niwa et al., 2000; Osorno et al., 2012). With this system, we identified




Figure 1. Dynamic expression of lncRNA *Ephemeron* during exit from naïve pluripotency. **(A)** Bioinformatic analysis of potential lncRNA candidates in naïve state regulation based on published transcriptome data for lncRNA and pluripotency related gene knockdowns. Each dot represents the effect on ESC (x-axis) and EpiSC (y-axis) gene signatures when a given gene is knocked down. **(B)** RT-qPCR detection of *Eprn* expression relative to β -actin upon 2i/LIF withdrawal. Mean \pm SD, n = 3. **(C)** Northern blotting of *Eprn*, *Nanog* and β -actin in ESCs in 2i/LIF or withdrawn from 2i/LIF for 24 hr, EpiSCs and MEF. * indicates a cross-hybridising RNA species since part of the probe region overlaps with LINE1-L1 and ERVK TEs. **(D)** RNA-FISH for *Eprn* upon 2i/LIF withdrawal with quantification of average hybridisation signals per cell. Mean value of total hybridisation signals for all cells \pm SD, n = 2. **(E)** *Eprn* expression relative to β -actin upon 2i/LIF component withdrawal quantified by RT-qPCR. Cells cultured in 2i/LIF and were transferred to N2B27 containing indicated single or dual factors for 24 hr. Mean \pm SD, n = 3. **F**, *Eprn* expression relative to β -actin upon PD/LIF withdrawal quantified by RT-qPCR. Mean \pm SD, n = 3.

DOI: 10.7554/eLife.23468.002

The following source data and figure supplements are available for figure 1:

Source data 1. Bioinformatics analysis of all lncRNAs and protein coding genes plotted in **Figure 1A**.

DOI: 10.7554/eLife.23468.003

Source data 2. Expression of potential lncRNA candidates in facilitating naïve state exit.

DOI: 10.7554/eLife.23468.004

Figure supplement 1. Molecular characterisation of *Ephemeron*.

DOI: 10.7554/eLife.23468.005

Figure supplement 2. *Eprn* expression and promoter methylation.

DOI: 10.7554/eLife.23468.006

lncRNAs that increased ESC and decreased EpiSC signatures when knocked down, suggestive of a possible role in transition from the ESC state (**Figure 1A** bottom right quadrant).

We examined expression profiles of these candidate lncRNAs during exit from self-renewal in defined conditions, exploiting the Rex1::GFP (RGd2) reporter ESC cell line (**Kalkan et al., 2017; Wray et al., 2011**) (**Figure 1—source data 2**). Upon 24 hr of 2i withdrawal, Rex1 expression status can discriminate subpopulations of cells with distinct functional properties, with Rex1-GFP high cells corresponding to undifferentiated ESCs and loss of GFP marking extinction of ESC identity (**Kalkan et al., 2017**). Amongst the 16 candidates analysed, *linc1281* (Refseq entry D630045M09Rik) (**Figure 1—figure supplement 1A**) was the third highest expressed lncRNA across all time points. Notably this lncRNA showed a distinctive profile during the first 24 hr, with differential expression observed between Rex1-GFP high and low cells (**Figure 1B, Figure 1—figure supplement 1B**). Due to its dynamic and transient expression profile, we designated *linc1281* as *Ephemeron* (*Eprn*). Ribosomal profiling analysis indicated that *Eprn* is indeed a non-coding RNA, with the longest predicted open reading frame (80 amino acids) possessing a ribosome release score typical of a non-coding sequence (**Guttman et al., 2013**). *Eprn* is located in a region of high transposable element (TE) content, with its exons comprised of 76.4% annotated TE sequences (including ERV-K, LINE L1, and SINE B2 elements, **Figure 1—figure supplement 1A**). This genomic region exhibits minimal sequence conservation in mammals (**Figure 1—figure supplement 1A**) and we failed to identify any human homologue either within the syntenic region or elsewhere in the human genome. However, a positionally conserved spliced transcript (CA504619) that shares 79% sequence identity to exon 3 of mouse *Eprn* is present within the rat syntenic region (**Figure 1—figure supplement 1C**). Therefore, it is likely that *Eprn* is conserved in rodents over 30 million years since the mouse-rat lineage divergence.

We conducted RT-qPCR, Northern blotting and RNA-FISH to evaluate expression, transcription variants and subcellular localisation of *Eprn* in ESCs. *Eprn* showed strong induction within 12 hr of 2i/LIF withdrawal, but decreased subsequently (**Figure 1B–D**). In EpiSCs or mouse embryonic fibroblasts (MEFs), *Eprn* expression was below the detection limit (**Figure 1C**). Consistent with the UCSC gene annotation, Northern blotting of total ESC RNA confirmed the expression of a single *Eprn* transcript over 1 kb in length (**Figure 1C, Figure 1—figure supplement 1D**). Transcription start and end sites of *Eprn* mapped by 5' and 3' RACE were in agreement with the annotation (**Figure 1—figure supplement 1E,F**). After 24 hr of 2i/LIF withdrawal, *Eprn* RNA-FISH hybridisation signals displayed predominantly cytoplasmic localisation, but from 48 hr onwards the remaining signals were mostly in the nucleus (**Figure 1D**).

To explore the regulation of *Eprn*, two inhibitors and LIF were withdrawn singly or dually for 24 hr. In conditions lacking Gsk3 inhibitor CHIRON99021 (CH), *Eprn* was upregulated (**Figure 1E**). When transferred to non-supplemented N2B27 medium from PD/LIF, *Eprn* expression was maintained for 24 hr before declining (**Figure 1F**). The addition of CH to LIF/serum culture reduced *Eprn* expression within 24 hr irrespective of the presence of MEK inhibitor PD0325901 (PD) (**Figure 1—figure supplement 1G,H**). Therefore, *Eprn* is suppressed by CH in self-renewing ESCs.

Through analysis of published data, we found that during early mouse development, *Eprn* expression peaked at E4.5 and was present in both epiblast and primitive endoderm of the mature blastocyst, but absent or low in E5.5 post-implantation epiblast (**Figure 1—figure supplement 2A**) and later stages between E7 and E17 (**Figure 1—figure supplement 2B**). Amongst adult tissues analysed, *Eprn* was only detected in kidney, and at a much lower level than in ESCs. We also observed that *Eprn* expression is restored upon naïve state resetting from EpiSCs (**Guo et al., 2009; Yang et al., 2010**) (**Figure 1—figure supplement 2C,D**). We conclude that *Eprn* expression is highly specific to ESCs and the early mouse embryo.

LINE and ERVL-MaLR elements are present within the *Eprn* proximal promoter region (2 kb upstream of TSS) (**Figure 1—figure supplement 1A**). Such repetitive elements gain DNA CpG methylation dramatically during pre- to post-implantation transition (**Smith et al., 2014**). By examining published data from embryos (**Seisenberger et al., 2012; Wang et al., 2014**) and ESC progression in vitro (**Kalkan et al., 2017**), we found that CpG methylation gain at the *Eprn* promoter was more extensive in the primed E6.5 epiblast (3% to 80%) than the average changes across all promoters (9% to 35%) or the genome (24% to 70%) (**Figure 1—figure supplement 2E**). In contrast, no major CpG methylation gain at *Eprn* promoter was present 24 hr post 2i withdrawal. These data suggest

that promoter methylation does not initiate *Eprn* repression, but could contribute to maintain silencing in later epiblast.

Loss of Ephemeron delays exit from naïve pluripotency

Initiation of ESC differentiation in defined media upon withdrawal of self-renewal factors recapitulates features of peri-implantation epiblast development (Kalkan *et al.*, 2017). The latency of naïve state exit varies, however, according to the starting self-renewal condition (Dunn *et al.*, 2014; Wray *et al.*, 2011). Higher activity of the core network in PD/LIF compared with 2i results in slower network dissolution, reflected in later onset of RGD2 downregulation (Dunn *et al.*, 2014). These two conditions feature different levels of *Eprn* due to CH mediated suppression in 2i (Figure 1E). We generated *Eprn* knockout (KO) ESCs via sequential gene targeting (Figure 2—figure supplement 1) and examined the phenotype in each condition. In steady state self-renewal, *Eprn* loss did not affect the Rex1-GFP profile in either case (Figure 2A,B). Upon transfer to N2B27, *Eprn* KO cells displayed delayed downregulation of GFP compared to parental cells, measured at 24 hr from 2i culture and 40 hr from PD/LIF culture (Figure 2B). By 72 hr, however, GFP expression was fully extinguished from either starting condition (Figure 2—figure supplement 2A). A transient delay in GFP downregulation in both culture conditions was also evident upon *Eprn* knockdown using siRNAs (Figure 2—figure supplement 2B). To assess the effect of *Eprn* depletion functionally, we conducted colony forming assays. Cells maintained in PD/LIF were subjected to 40 hr culture in N2B27 and then replated at clonal density in 2i/LIF to assay the persistence of ES self-renewal potential (Betschinger *et al.*, 2013). *Eprn* KO and knockdown cells both gave rise to substantially more undifferentiated colonies than wild type controls (Figure 2C,D, Figure 2—figure supplement 2C). Considered together, these results indicate that *Eprn* deficiency impairs timely exit from naïve pluripotency.

Molecular consequences of Ephemeron loss

We performed RNA-sequencing and compared the transcriptome of wild type and *Eprn* KO ESCs using three independently targeted KO ESC lines and three subclones of the parental wild type ESCs. Sixteen genes were differentially expressed between wild type and *Eprn* KO cells both in PD/LIF and after 8 hr withdrawal (Benjamini-Hochberg adjusted $p < 0.05$, fold change > 1.5 or < 0.7) (Figure 2—figure supplement 2D) (Figure 2—figure supplement 2E). These include *Tcf15*, which has been associated with transition from the naïve state and has an inverse expression pattern compared to naïve pluripotency factors (Davies *et al.*, 2013). *Lin28a* was the most differentially expressed gene in the group, with *Eprn* KO cells displaying a twofold reduction in mean expression level (Figure 2E). Although *Lin28a* is commonly considered as a core pluripotency factor, its expression is actually increased when cells transition out of the naïve state in vivo and in vitro (Boroviak *et al.*, 2015; Kalkan *et al.*, 2017; Kumar *et al.*, 2014; Marks *et al.*, 2012). Attenuated downregulation of members of the naïve transcription factor network is one explanation for delayed exit from the ESC state (Kalkan and Smith, 2014). We hypothesised that *Lin28a* could be a negative regulator of the network. We examined expression of naïve pluripotency transcription factors in *Eprn* KO cells and found a higher level of *Nanog* mRNA (Figure 2E, Figure 2—figure supplement 2F). To characterise the profile of naïve pluripotency dissolution further in *Eprn* KO cells, a PD/LIF withdrawal time course was monitored over 24 hr. The two-fold reduction in *Lin28a* mRNA in *Eprn* KO cells was constant throughout this time course (Figure 2F). Conversely, *Nanog* transcript and protein levels remained higher at 16 hr and 24 hr respectively (Figure 2F, see also 3E,F for protein). Mean *Klf2* transcript levels appeared higher in *Eprn* KO cells, but below statistical significance. Other members of the naïve network showed similar expression profiles in wild type and *Eprn* KO cells (Figure 2—figure supplement 2F). Among peri-implantation epiblast markers, upregulation kinetics for *Fgf5* were unchanged in *Eprn* KO cells, but transcripts for *Dnmt3a*, *Dnmt3b* and *Oct6* remained lower from 16 to 24 hr (Figure 2—figure supplement 2F). Although not statistically significant, *Otx2* transcripts appeared modestly reduced throughout the time course, which could be related to the elevated expression of *Nanog* (Acampora *et al.*, 2016).

We restored *Eprn* expression in KO cells by inserting the *Eprn* genomic region under control of the human *EF1 α* promoter into the deleted locus (Figure 2—figure supplement 3A,B). The rescue cells displayed a wild type exit profile as measured by GFP profile 40 hr post PD/LIF withdrawal




Figure 2. Absence of *Ephemerin* delays exit from naive pluripotency. **(A)** Experimental scheme for analysing naive state exit using Rex1GFPd2 reporter cells. **(B)** Rex1-GFP flow cytometry profiles of wild type and *Eprn* KO cells in 2i and PD/LIF and during transition from these starting conditions. Two independent clones for wild type and *Eprn* KO cells were analysed. Percentage of GFP high cells were quantified. **(C)** Experimental scheme for colony formation assay. **(D)** Colony formation assay for wild type and *Eprn* KO cells in 2i/LIF 40 hr post PD/LIF withdrawal. Colonies were stained with alkaline phosphatase (AP), with representative images shown. Percentage clonogenicity was calculated by the number of AP positive colonies divided by the total number of cells plated. Mean \pm SD, $n = 3$. **(E)** *Lin28a* and *Nanog* expression relative to β -actin in three independent wild type and *Eprn* KO cell lines measured by RT-qPCR. Mean \pm SE, $n = 3$. * $p < 0.05$, ** $p < 0.01$, student's *t*-test. **(F)** *Nanog* and *Lin28a* expression kinetics upon PD/LIF withdrawal in wild type and *Eprn* KO cells. Mean \pm SD, $n = 3$. **(G)** Rex1-GFP flow cytometry profile for wild type, *Eprn* KO and *Eprn* rescue cells 40 hr post PD/LIF withdrawal. Percentage of GFP high cells were quantified.

DOI: 10.7554/eLife.23468.007

The following figure supplements are available for figure 2:

Figure supplement 1. Generation of *Eprn* KO ESCs.

DOI: 10.7554/eLife.23468.008

Figure supplement 2. Phenotypic and molecular characterisation of *Eprn* KO during naive state exit.

DOI: 10.7554/eLife.23468.009

Figure supplement 3. Generation of *Ephemerin* KO rescue ESCs.

Figure 2 continued on next page

Figure 2 continued

DOI: 10.7554/eLife.23468.010

Figure supplement 4. Differentiation capacity of *Eprn* KO ESCs.

DOI: 10.7554/eLife.23468.011

(**Figure 2G**). *Lin28a* and *Nanog* expression levels were similar to wild type cells (**Figure 2—figure supplement 3C**).

To explore the differentiation capacity of *Eprn* KO cells, we conducted in vitro differentiation assays directing ESCs towards EpiSCs and somatic lineages (**Figure 2—figure supplement 4**). Both wild type and *Eprn* KO ESCs could be differentiated into EpiSCs using N2B27 supplemented with ActivinA/Fgf2/XAV939 (Sumi et al., 2013) on fibronectin. Such in vitro differentiated EpiSCs could be stably propagated over multiple passages, and displayed typical morphology and gene expression irrespective of genotype (**Figure 2—figure supplement 4A,B**). We also applied neuronal, mesendoderm and definitive endoderm differentiation protocols to *Eprn* KO ESCs and found that lineage markers were induced, with a slight delay for mesendoderm (**Figure 2—figure supplement 4C–E**). Thus retarded naïve state exit does not notably impair subsequent lineage commitment capacity.

The Ephemeron genetic network includes *Lin28a* and *Nanog*

Based on the preceding data, we hypothesised that *Lin28a* could be a downstream effector of *Eprn*, acting to reduce expression of *Nanog*. To characterise further the relationship between *Eprn*, *Lin28a* and the naïve transcription factor network, we carried out a series of genetic perturbation experiments and measured both Rex1-GFP reporter dynamics and colony formation upon withdrawal from PD/LIF. In *Eprn* KO cells, *Nanog* knockdown partially restored downregulation of Rex1-GFP 40 hr after PD/LIF withdrawal, and colony formation was reduced to the low level observed in wild type cells subjected to *Nanog* siRNA (**Figure 3A**). Knockdown of *Klf4* had no effect on exit kinetics from PD/LIF in either wild type or *Eprn* KO cells. Knockdowns of other naïve transcription factors, *Esrrb*, *Tfcp2l1* and *Klf2*, accelerated exit in wild type cells but in contrast to *Nanog* depletion this phenotype was attenuated in *Eprn* KO cells (**Figure 3—figure supplement 1B**). Resistance of *Eprn* KO cells to accelerated transition upon *Esrrb*, *Tfcp2l1* and *Klf2* knockdown could be attributed to elevated *Nanog*. We therefore conducted dual knockdown experiments (**Figure 3—figure supplement 1C**). Simultaneous depletion of *Esrrb*, *Tfcp2l1* or *Klf2* together with *Nanog* largely abolished the effect of *Eprn* KO on GFP downregulation (**Figure 3—figure supplement 1C,D**). These data are consistent with *Eprn* acting, at least in part, via modulation of *Nanog* expression.

We investigated whether lowered expression of *Lin28a* contributes to the slower exit from naïve pluripotency and the increased *Nanog* expression. We manipulated *Lin28a* dosage by either overexpression or knockdown in *Eprn* KO cells. In wild type cells, *Lin28a* overexpression had no significant effect. In *Eprn* KO cells, however, it restored normal transition kinetics (**Figure 3B**). Conversely, *Lin28a* knockdown phenocopied *Eprn* loss, delaying exit from naïve pluripotency (**Figure 3C**). Concomitant knockdown of *Nanog* and *Lin28a* abolished this effect (**Figure 3C**). *Lin28a* knockdown cells exhibited marginally elevated *Nanog* mRNA in PD/LIF and persistence at higher levels after 8 hr of PD/LIF withdrawal (**Figure 3D**). At the protein level, *Eprn* null cultures displayed more cells with high *Nanog* and low *Lin28a* expression at the 24 hr time point as quantified by co-immunostaining (**Figure 3E,F**, **Figure 3—figure supplement 1E**). Interestingly, *Lin28a* was detected as concentrated foci in the nucleus and also in the cytoplasm (observed with two independent antibodies), and both nuclear and cytoplasmic expression were increased after PD/LIF withdrawal (**Figure 3—figure supplement 1F**). During early embryo development, expression of *Lin28a* and *Eprn* are positively correlated, while *Lin28a* and *Nanog* are negatively correlated (**Figure 3—figure supplement 1G**) (Ohnishi et al., 2014). These data are consistent with the proposition that *Lin28a* is genetically downstream of *Eprn* and may facilitate exit from naïve pluripotency by accelerating downregulation of *Nanog*.

To assess whether *Eprn* could regulate *Lin28a* or *Nanog* expression directly, we employed chromatin isolation by RNA purification (ChIRP) (Chu et al., 2011). Using this method, we were able to selectively pull down endogenous *Eprn* RNA (**Figure 3—figure supplement 2A**). However, we did




Figure 3. Lin28a is downstream of *Epheron* and regulates Nanog expression. (A) Rex1-GFP flow cytometry profiles (Left) and colony formation capacity (Right) 40 hr post PD/LIF withdrawal for wild type and *Eprn* KO cells transfected with indicated siRNAs. (B) Rex1-GFP flow cytometry profiles and colony formation capacity 40 hr post PD/LIF withdrawal for wild type and *Eprn* KO cells transfected with Lin28a expression vector. (C) Rex1-GFP flow cytometry profile and colony formation capacity 40 hr post PD/LIF withdrawal with Nanog and Lin28a single or dual knockdowns in wild type cells. Quantification of percentage of GFP high cells were shown in (A-C). Percentage clonogenicity in (A-C) is measured by the number of AP positive colonies divided by the total number of cells plated, with representative AP staining images shown. Mean \pm SD, n = 3. (D) *Lin28a* and *Nanog* expression relative to β -actin upon PD/LIF withdrawal in *Lin28a* knockdown and control cells. Mean \pm SD, n = 3. *p<0.05, Student's t-test. (E) Correlation of Nanog and Lin28a protein expression immunostaining in wild type and *Eprn* KO cells 24 hr post PD/LIF withdrawal. (F) Representative images of cells co-immunostained with Nanog and Lin28a and quantified in E.

DOI: 10.7554/eLife.23468.012

The following figure supplements are available for figure 3:

Figure supplement 1. Characterisation of *Eprn*, Nanog and Lin28a genetic interaction.

DOI: 10.7554/eLife.23468.013

Figure supplement 2. *Eprn* does not act on chromatin.

DOI: 10.7554/eLife.23468.014

not detect chromatin enrichment at the *Lin28a* or *Nanog* promoter regions (**Figure 3—figure supplement 2B–D**). Indeed, no significant enrichment genome-wide was observed in wild type compared to *Eprn* KO cells (**Figure 3—figure supplement 2E**). Thus we found no evidence that *Eprn* functions by chromatin association (**Rinn and Guttman, 2014**).

The H3K4me3 modification was reduced at the *Lin28a* promoter in *Eprn* KO cells, in line with reduced transcription (**Figure 3—figure supplement 2F**). One explanation for anti-correlated expression could be direct negative regulation of *Lin28a* by *Nanog*. We inspected two published *Nanog* chromatin immunoprecipitation (ChIP) sequencing datasets (**Chen et al., 2008; Marson et al., 2008**) but observed no localisation of *Nanog* at the *Lin28a* locus (**Figure 3—figure supplement 2G**). Furthermore, we did not observe *Lin28a* upregulation in *Nanog* knockdown cells (**Figure 3—figure supplement 2H**). Therefore, *Nanog* does not appear to be a direct upstream regulator of *Lin28a*.

The function of *Lin28a* in ESC transition may be mediated by suppression of *let-7g*

Lin28a is an RNA binding protein with a well-established function in suppressing maturation of *let-7* family miRNAs (**Cho et al., 2012; Viswanathan et al., 2008**). We investigated whether the role of *Lin28a* in naïve state exit is *let-7* dependent. We profiled mature miRNA expression of *let-7* family members using RT-qPCR. Expression of *let-7a*, *let-7d*, *let-7e*, *let-7g* and *let-7i* decreased 24 hr after 2i/LIF withdrawal, coincident with the increase in *Lin28a* expression (**Figure 4A**). Mature miRNA *let-7c* expression was unaffected, suggesting that *let-7c* expression is independent of *Lin28a*. This observation is in agreement with a recent finding that *let-7c-2*, the major *let-7c* isoform expressed in mouse ESCs, bypasses *Lin28a* regulation due to lack of a GGAG recognition motif in its loop region (**Triboulet et al., 2015**). The *Lin28a* regulated *let-7* miRNAs, but not *let-7c*, are expressed at higher levels in ESCs in 2i/LIF than in LIF/serum (**Pandolfini et al., 2016**) (**Figure 4—figure supplement 1A**), consistent with lower *Lin28a* in 2i/LIF.

To examine the role of *Lin28a* regulated *let-7* miRNAs in naïve state exit, we first transfected ESCs with mature *let-7g* mimic. We used *let-7g* as a representative member since all apart from *let-7e* share the same seed sequence (**Figure 4—figure supplement 1B**). Forced expression of *let-7g* in RGd2 cells resulted in delayed GFP downregulation upon both 2i and PD/LIF withdrawal (**Figure 4B**). Elevated ESC colony formation capacity post PD/LIF withdrawal was also observed (**Figure 4C**). To identify downstream targets of *let-7g*, we curated genes that are upregulated upon 2i withdrawal in our RNA-sequencing dataset and searched for known or predicted *let-7g* targets using the RNA22 tool (**Miranda et al., 2006**). DNA methyltransferases *Dnmt3a* and *Dnmt3b* emerged as prime candidates, as has previously been proposed (**Kumar et al., 2014**). Expression of both increases during ESC transition (**Kalkan et al., 2017**). *Dnmt3a/3b* transcript levels were lower in *Eprn* KO cells than wild type control (**Figure 2—figure supplement 2F**). Multiple *let-7g* target sites were predicted by RNA22 within the *Dnmt3a* 3'UTR and one site in the *Dnmt3b* 3'UTR (**Figure 4D, Figure 4—figure supplement 1C**). ESCs were co-transfected with mature *let-7g* mimic and luciferase constructs containing the entire 3'UTRs of *Dnmt3a* and *Dnmt3b*. *let-7g* reduced luciferase expression by more than 60% relative to scrambled control (**Figure 4E**), suggesting that *Dnmt3a/3b* transcripts are indeed *let-7g* targets. To test specificity of this repression, we generated two *Dnmt3b* 3'UTR luciferase reporter constructs with the *let-7* seed recognition site mutated (**Figure 4—figure supplement 1D**). These mutant reporters escaped repression by the *let-7g* mimic (**Figure 4—figure supplement 1D**).

Dnmt3a and *Dnmt3b* methylate the *Nanog* promoter during naïve state exit

Epiblast progression is associated with genome-wide de novo methylation during pre- to post-implantation development (**Auclair et al., 2014**). This phenomenon is recapitulated when naïve ESCs are withdrawn from 2i (**Kalkan et al., 2017**). Previous studies demonstrated hypomethylation of the *Nanog* promoter in mouse ESCs compared to lineage committed cells (**Farthing et al., 2008; Yu et al., 2007**). We speculated that impeded de novo DNA methylation could allow perdurance of *Nanog* expression at the onset of naïve state exit. To investigate this hypothesis, we carried out bisulfite sequencing analysis across the *Nanog* proximal promoter region, 1 kb upstream of the TSS,




Figure 4. Lin28a function is mediated via members of *let-7* miRNAs. (A) Mature *let-7* family microRNA expression quantified by RT-qPCR in 2i/LIF, 24 hr post 2i/LIF withdrawal, and EpiSCs. (B) Rex1-GFP flow cytometry profile upon forced expression of mature *let-7g* mimic during transition from 2i and PD/LIF. Quantification of percentage of GFP high cells was shown. (C) Colony formation assay in 2i/LIF of cells with forced expression of *let-7g* mimic and control 40 hr post PD/LIF withdrawal. Colonies were stained with alkaline phosphatase (AP). Percentage clonogenicity was calculated by the number of AP positive colonies divided by the total number of cells plated. Mean \pm SD, $n = 3$. (D) Predicted target sites of *let-7g* in 3'UTRs of *Dnmt3a* and *Dnmt3b* by RNA22. (E) Dual luciferase assay measuring repression by *let-7g* mediated through 3'UTRs of *Dnmt3a* and *Dnmt3b*. Fold repression of Luc/Rluc relative to scramble was plotted. Mean \pm SD, $n = 3$. (F) Relative expression normalised to β -actin of naïve and peri-implantation epiblast associated genes in ESCs with forced expression of *let-7g* mimics. Mean \pm SD, $n = 3$.

DOI: 10.7554/eLife.23468.015

The following figure supplement is available for figure 4:

Figure supplement 1. *let-7* family mature miRNA expression, sequence and predicted *let-7g* sites in the 3'UTRs of *Dnmt3a* and *Dnmt3b*.

DOI: 10.7554/eLife.23468.016

after siRNA knockdown of *Dnmt3a/3b* singly or together (**Figure 5A**). We observed a marked reduction of CpG methylation in the -1 kb to -761 bp region (region 1) 40 hr after PD/LIF withdrawal (**Figure 5A**). Cells transfected with scrambled control siRNA exhibited 40% CpG methylation at scored sites, whereas *Dnmt3b* depleted cells displayed 18% CpG methylation and *Dnmt3a* or *Dnmt3a/b* double knockdown cells showed only around 8%. Effects were less obvious in the -538 bp to $+18$ bp region (region 2), which was barely methylated at this time point. These data suggest that *Dnmt3a* and *Dnmt3b* have overlapping roles in mediating de novo methylation at the *Nanog* proximal promoter. *Eprn* KO cells also exhibited reduced methylation at the *Nanog* promoter, with region one again showing a more prominent reduction (**Figure 5—figure supplement 1A**).

To explore the role of de novo DNA methylation in ESC transition, we investigated functional consequences of *Dnmt3a* and *Dnmt3b* depletion. We created *Dnmt3a* and *Dnmt3b* single and compound knockouts in RGd2 ESCs using CRISPR/Cas9. Using two guide RNAs (gRNAs), we generated deletions of highly conserved PC and ENV motifs (motifs IV and V) within the catalytic domain for both *Dnmt3a* and *Dnmt3b*, recapitulating the previously characterised *Dnmt3b* and *Dnmt3b* mutant gene structures (*Okano et al., 1999*) (**Figure 5—figure supplement 1B**). *Dnmt3a* and *Dnmt3b* single and double KO cells exhibited delayed Rex1-GFP downregulation (**Figure 5B**). Colony formation capacity of the single and double KO cells 40 hr post PD/LIF withdrawal confirmed slower extinction of ESC identity (**Figure 5C**). Interestingly, however, as with *Eprn* KO, the delay in GFP downregulation did not endure (**Figure 5—figure supplement 1C**). Absence of *Dnmt3a* and *Dnmt3b* singly or together was associated with transient perdurance of *Nanog* expression (**Figure 5D**). At 8 hr after PD/LIF withdrawal, *Nanog* mRNA in *Dnmt3a* and/or *Dnmt3b* mutants was equivalent to wild type cells in PD/LIF, whereas wild type cells had downregulated *Nanog* expression by 50% (**Figure 5D**). We also observed elevated expression of *Tfcp2l1*, *Klf2*, *Klf4* and *Tbx3* in *Dnmt3a/3b* single or compound KO cells (**Figure 5—figure supplement 1E**). The promoters of these genes are methylation refractory in the 2i withdrawal time course (*Kalkan et al., 2017*). Therefore, the elevated expression should be secondary to some other factor(s) such as increased *Nanog*. *Dnmt3a/3b* compound KO also resulted in impeded upregulation of peri-implantation markers *Fgf5*, *Oct6* and *Otx2* at 24 hr post PD/LIF withdrawal (**Figure 5—figure supplement 1F**). These data indicate that de novo DNA methylation facilitates timely progression from the ESC state. Importantly, however, methylation by *Dnmt3a/3b* is not essential for the exit from naïve pluripotency.

Discussion

Mouse ES cell self-renewal is robust due to recursive wiring of a core transcription factor network (*Dunn et al., 2014; Martello and Smith, 2014; Young, 2011*). Rapid developmental progression from such a resilient state is achieved through parallel mechanisms. In this study, we find that a lncRNA, *Ephemeron*, participates in the timely dissolution of naïve identity. Genetic interactions link *Eprn* with known players in post-transcriptional and epigenetic regulation (**Figure 5E**). *Eprn* lies upstream of *Lin28a/let-7g* and *Dnmt3a/3b*, and ultimately contributes to timely downregulation of the pivotal naïve transcription factor *Nanog*. *Eprn* depletion reduces *Lin28a* expression, although the molecular mechanism underlying this effect remains unclear. Lower *Lin28a* stabilises expression of the *let-7* miRNAs whose targets include de novo DNA methyltransferases *Dnmt3a* and *Dnmt3b*. Resulting decreased *Dnmt3a/3b* reduces *Nanog* proximal promoter CpG methylation, correlating with transiently perduring expression. This lncRNA/miRNA/DNA methylation module provides an additional layer in the multi-layered machinery that enforces transition from naïve to formative pluripotency (*Acampora et al., 2016; Jang et al., 2017; Kalkan et al., 2017; Kalkan and Smith, 2014; Smith, 2017*).

Eprn promotes ESC transition and is suppressed by Gsk3 inhibition during ground state self-renewal in 2i or 2i/LIF. ESCs cultured without Gsk3 inhibition can self-renew in the presence of PD/LIF or LIF/serum. In these conditions they express *Eprn* and higher levels of *Lin28a*. The lack of overt consequence is presumably due to the dominant self-renewal environment provided by Stat3 activation and MEK inhibition that sustain expression of *Nanog* and other naïve factors. Nonetheless, loss of *Eprn* in PD/LIF resulted in elevated *Nanog* and delayed transition kinetics.

We observed a Mendelian ratio of homozygous *Eprn* mutant mice from heterozygous intercrosses (5:18:7, wild type: heterozygous: homozygous offspring). Therefore, in common with *Lin28a* (*Shinoda et al., 2013*), *Eprn* is dispensable for development of laboratory mice. Some protein-




Figure 5. Loss of Dnmt3a and Dnmt3b delays naïve state exit associated with transient persistence of Nanog expression. (A) Bisulfite sequencing analysis of *Nanog* proximal promoter CpG island DNA methylation in *Dnmt3a* and *Dnmt3b* single and dual knockdown cells at 40 hr post PD/LIF withdrawal. The positions of cytosines analysed (mm10) are indicated on the left panel. Black and white circles represent methylated and unmethylated cytosine respectively. (B) Rex1-GFP flow cytometry profiles of *Dnmt3a* and *Dnmt3b* single and dual KO cells withdrawn from 2i or PD/LIF for 24 and 40 hr respectively. Percentage of GFP high cells were quantified. (C) colony formation capacity 40 hr post PD/LIF withdrawal for *Dnmt3a* and *Dnmt3b* single and compound KO cells. Percentage clonogenicity was measured by the number of AP positive colonies formed divided by the total number of cells plated, with representative AP staining images shown. Mean \pm SD, n = 3. (D) Expression of *Nanog* relative to β -actin in *Dnmt3a* and *Dnmt3b* single

Figure 5 continued on next page

Figure 5 continued

and compound KO cells quantified by RT-qPCR. Mean \pm SD, n = 2. (E) Schematic representation of the inferred *Eprn* pathway. Legends for Figures and Source Data.

DOI: [10.7554/eLife.23468.017](https://doi.org/10.7554/eLife.23468.017)

The following figure supplement is available for figure 5:

Figure supplement 1. Phenotypic and molecular characterisation of *Dnmt3a/3b* KO in naïve state exit.

DOI: [10.7554/eLife.23468.018](https://doi.org/10.7554/eLife.23468.018)

coding genes that exhibit demonstrable loss-of-function phenotypes in ESC self-renewal or transition also show no early embryo phenotype (Leeb et al., 2014; Martello and Smith, 2014). Our interpretation is that ESCs provide a sensitised platform for identifying components whose functions may be compensated during in vivo development.

The majority of lncRNAs are not phylogenetically conserved (Necsulea et al., 2014). Due to their rapidly evolving nature, it is thought that lncRNAs are likely to acquire species or lineage-restricted functions and several examples have recently been described (Durruthy-Durruthy et al., 2016; Paralkar et al., 2014; Rani et al., 2016). The presence of *Eprn* exclusively in rodent may be associated with rapid embryonic progression from pre-implantation epiblast to gastrulation (Rossant and Tam, 2017), which necessitates acute extinction of the naïve pluripotency programme (Smith, 2017). lncRNAs are more tolerant to TE integration than protein coding genes, which could drive more rapid evolution (Kelley and Rinn, 2012; Necsulea et al., 2014). Non-coding transcripts harbouring TE sequences are enriched in ESCs and early embryo development in both mouse and human (Fort et al., 2014; Göke et al., 2015; Kelley and Rinn, 2012) and in several instances have been proposed to regulate pluripotency (Durruthy-Durruthy et al., 2016; Fort et al., 2014; Lu et al., 2014). *Eprn* is comprised of 76.4% TEs, compared to the average of 41.4% TE composition in the mouse genome and 33% reported for mouse multi-exon lincRNA sequences (Kelley and Rinn, 2012). The aligned sequence between *Eprn* and the rat transcript from the syntenic region includes ERVK LTR and SINE B2 elements. These sequences have been preserved for over 30 million years since the mouse-rat lineage divergence.

Lin28a is known as a human somatic cell reprogramming factor (Yu et al., 2007). However, *Lin28a* is expressed at a lower level in ground state mouse ESCs (Marks et al., 2012) and pre-implantation epiblast, than in post-implantation epiblast and EpiSCs (Boroviak et al., 2015). The expression pattern is consistent with our evidence that up-regulation of *Lin28a* at the onset of mouse ESC differentiation functions to facilitate transition from the naïve state. During human iPSC generation, *Lin28a* may promote acquisition of primed pluripotency, the endpoint for current human somatic cell reprogramming. *Lin28a* itself is a target of *let-7* miRNAs (Kumar et al., 2014; Melton et al., 2010) and the reciprocal negative feedback loops can act as a bimodal switch. Our findings are consistent with the recent report that loss of *Lin28a* reduced ESC heterogeneity in serum/LIF, favouring a more naïve state (Kumar et al., 2014). This effect was attributed to *let-7g*. We note, however, that *Lin28a* can post-transcriptionally regulate the expression and/or translation of many RNAs independently of *let-7* (Cho et al., 2012; Zhang et al., 2016) that could also contribute to ESC transition.

De novo methyltransferases *Dnmt3a/3b* have previously been proposed as targets of *let-7g* (Kumar et al., 2014). Our results show that loss of *Dnmt3a* and *Dnmt3b*, individually and in combination, delays naïve state exit. Naïve ESCs (Ficz et al., 2011; Habibi et al., 2013; Leitch et al., 2013) and pre-implantation epiblast (Monk et al., 1987; Sanford et al., 1987) have low expression of *Dnmt3a/3b* and display global DNA hypomethylation. However, the post-implantation epiblast rapidly acquires global DNA methylation and this process is dependent on *Dnmt3a/3b* (Auclair et al., 2014). A similar acute trend is observed upon naïve ESC withdrawal from 2i (Kalkan et al., 2017). Early de novo methylation may have functional consequences for specific naïve pluripotency associated factors, such as *Nanog*, enduring rapid downregulation. It is noteworthy, however, that the *Dnmt3a/3b* KO phenotype is transient and ESC identity still collapses. Therefore, although de novo DNA methylation facilitates ESC transition it is not mandatory for the exit from naïve pluripotency.

Human naïve pluripotency shares molecular and cellular features with mouse, consistent with a conserved core pluripotency programme in mammals (Guo et al., 2017, 2016; Smith, 2017;

Takashima et al., 2014; Theunissen et al., 2014). However, species-specific differences are evident. Notably, Gsk3 inhibition has less impact on human naïve state maintenance (*Guo et al., 2017; Theunissen et al., 2016*). This is partly explained by the lack of *ESRRB* expression in human pluripotent cells (*Blakeley et al., 2015; Martello et al., 2012; Takashima et al., 2014; Theunissen et al., 2014*), but absence of *Eprn* may be an additional factor that reduces requirement for Gsk3 inhibition.

In summary, we have mapped a genetic interaction module consisting of a novel lncRNA, proteins and miRNAs that is integrated into the multi-pronged molecular machinery that propels mouse ESCs towards lineage competence. The fine-tuning effect of *Eprn* could be representative of lncRNA actions in the regulation of molecular networks and illustrative of their potential contribution to species diversification.

Materials and methods

Targeting, expression and gRNA vector construction

BAC RP24-353A19 (C57BL/6J background) was obtained from Wellcome Trust Sanger Institute for constructing the *Eprn* knockout targeting vectors by recombineering using bacterial strain EL350 (*Lee et al., 2001*). Floxed drug resistant cassettes containing hygromycin B phosphotransferase gene (Hygro) or Blastidicin S-resistance gene (Bsd) were PCR amplified using chimeric primers miniU and miniD (**Supplementary file 1A**) harbouring 80 bp mini-homologies to the genomic region flanking *Eprn* locus. The purified PCR fragments *loxP*-PGK-Hygro-bghpA-*loxP* and *loxP*-PGK-Bsd-bghpA-*loxP* were used to replace the entire genomic region of *Eprn* locus with the drug resistant cassettes. The retrieval homology arms were PCR amplified using primers ReUF and ReUR for upstream and ReDF and ReDF for downstream mini-arms (**Supplementary file 1B**). The mini arms were subsequently cloned into pBS-MC1-DTA vector by 3-way ligation using restriction enzymes, SpeI, HindIII and XhoI. The mini-arm containing vector was linearised by HindIII and used to retrieve the targeting vectors from the modified BACs, giving rise to the final targeting vectors, HygroTV and BsdTV.

Lin28a overexpression vector was constructed by PCR cloning mouse *Lin28a* from cDNA using forward primer AATTGTCGACATGGGCTCGGTGTCCAACCAGCAGT and reverse primer AA TTGCGGCCGCTCAATTCTGGGCTTCTGGGAGCAG and cloned into pENTR2B vector. It was subsequently cloned into *PiggyBac*-based expression vector using Gateway LR clonase (Thermo Fisher Scientific, Waltham, MA, USA, 11791020) to generate pCAG-Lin28a-pA:PGK-hygro-pA plasmid.

The gRNA design was conducted using online CRISPR gRNA design tool <https://www.atum.bio/eCommerce/cas9/input>. The chosen gRNAs were based on minimal off-target scores. Deletions were designed to recapitulate the original Dnmt3a and Dnmt3b KO mutations (*Okano et al., 1999*), excising the highly conserved PC and ENV motifs (motifs IV and V) within the catalytic domain. The gRNAs were generated by annealing the indicated oligos (**Supplementary file 2A**), which were subsequently ligated into pX458 vector (Addgene) digested with BbsI. The constructs were sequence validated before transfection.

Cell culture

ESCs were cultured on 0.1% gelatin in 2i/LIF medium (homemade N2B27 base medium, supplemented with 1 μ M PD0325901, 3 μ M CHIR99021, and 20 ng/ml LIF) as described (*Ying et al., 2008*). For gene targeting, ESC were maintained with serum containing medium supplemented with 2i/LIF as above (KO-DMEM high glucose, 15% FCS, 2 mM L-Glutamine, NEAA, 1 mM Sodium Pyruvate (Thermo Fisher Scientific), 100 mM β -Mercaptoethanol (Sigma Aldrich, St. Louis, MO, USA). Correctly targeted clones were transferred to N2B27 based 2i/LIF medium for expansion and experimentation. The RGd2 reporter wild type subclones and *Eprn* KO ESC clones are of V6.5 origin (RRID:CVCL_C865). An independent wild type RGd2 reporter line is of E14 origin (RRID:CVCL_C320). All cell lines are mycoplasma negative by PCR screening in house.

Naïve pluripotency exit assays

ESCs were plated at $1 \times 10^4/\text{cm}^2$ in 2i without LIF or PD/LIF. The next day, cells were carefully washed with PBS before switching to N2B27 medium. Rex1-GFP profile was analysed at indicated

time points in at least two independent experiments using a Cyan or Fortessa FACs analyser. Live dead discrimination was performed using TO-PRO-3 (Thermo Fisher Scientific, T3605). For clonal assay, post 24 hr or 40 hr 2i or PD/LIF withdrawal respectively, 300–500 cells were plated per well of a 12 well plate coated with Laminin (1:100 dilution, Sigma Aldrich, L2020) and cultured in 2i/LIF for 6 days. Alkaline Phosphatase staining (Sigma Aldrich, 86R-1KT) was conducted to visualise ES colonies. AP-stained plates were imaged using an Olympus IX51, DP72 camera with CellSens software and subsequent colony counting was conducted manually using ImageJ software.

EpiSC derivation from ESCs and EpiSC resetting

ESCs were plated at $1 \times 10^4/\text{cm}^2$ in 2i/LIF on a gelatin coated plate. The next day, cells were washed with PBS before medium switch to N2B27 medium supplemented with 20 ng/ml Activin A and 12 ng/ml Fgf2 together with 2 μM XAV939 (Sigma Aldrich, X3004), A/F/X. Cells were then passaged to fibronectin coated plate in A/F/X medium. EpiSCs were passaged for at least seven times before gene expression analysis and resetting. For EpiSC resetting, EpiSCs were stably transfected with GY118F construct by *piggyBac* transposition (Yang *et al.*, 2010). 1×10^4 cells were plated in a one well of a 12 well plate in A/F/X, the next day, 2i plus GCSF was supplied to initiate resetting.

Differentiation assays

For neuronal differentiation, ESCs were plated at $1 \times 10^4/\text{cm}^2$ in N2B27 medium on laminin (1:100 in PBS) for up to 4 days for gene expression analysis. For mesendoderm differentiation, cells were plated at $0.6 \times 10^4/\text{cm}^2$ in N2B27 based medium containing 10 ng/ml ActivinA, 3 μM CHIR99021 on Fibronectin for up to 4 days for gene expression analysis. For definitive endoderm differentiation, cells were plated at $1.5 \times 10^4/\text{cm}^2$ in N2B27 based medium containing 20 ng/ml ActivinA, 3 μM CHIR99021, 10 ng/ml FGF4, 1 $\mu\text{g/ml}$ Heparin, 100 nM PI103. On day 2, the media was switched to SF5 based medium containing 20 ng/ml ActivinA, 3 μM CHIR99021, 10 ng/ml FGF4, 1 $\mu\text{g/ml}$ Heparin, 100 nM PI103 and 20 ng/ml EGF2. Per 100 ml SP5 basal medium, it contains 500 μl N2, 1 ml B27 without VitaminA supplement, 1% BSA, 1 ml L-glutamine and 100 μl β -mercaptoethanol. Detailed protocols can be found in Mulas *et al.* (Mulas *et al.*, 2017).

siRNA, miRNA mimics and plasmid transfection

siRNAs and miRNA mimics were obtained from Qiagen and the catalogue numbers are listed in **Supplementary file 3**. Transfection was performed using Dharmafect 1 (Dharmacon, Lafayette, CO, USA, T-2001–01) in a reverse transfection protocol with the final siRNA or miRNA mimics concentration to be 10 nM. Two siRNA combination were used per transfection for each target gene knockdown.

Plasmid transfection was performed using Lipofectamine 2000 (Thermo Fisher Scientific, 11668027) following the manufacturers protocol. For *piggyBac* based stable integration, a *piggyBac* transposon and hyperactive PBase (hyPBase) ratio of 3:1 was used.

Generation of Dnmt3a and Dnmt3b KO ESCs with CRISPR/Cas9

A pair of gRNA containing plasmids based on px458 backbone (Ran *et al.*, 2013) were transfected using Fugene HD (Promega, Madison, WI, USA, E2311). 100 ng of each plasmid were transfected with 0.6 μl Fugene HD (1:3 ratio) to 2×10^5 ESCs in suspension in 2i/LIF medium overnight. The next day, the media was refreshed and 48 hr post transfection, 1,000 GFP high cells were sorted into a well of a six well plate for colony formation. Individual colonies were picked and genotyping was conducted from extracted genomic DNA by triple primer PCR to identify clones with designed deletion (**Supplementary file 2B**). For Dnmt3a KO, deletion resulted in genotyping PCR product shift from 760 bp representing the wild type allele to 1132 bp. For Dnmt3b KO, deletion resulted in shift from 344 bp representing the wild type allele to 653 bp. Only homozygous mutants were chosen for subsequent experimentation.

Southern blotting

Genomic DNA of individually picked ESC clones was extracted and digested with *XmnI*, size-fractionated on a 0.8% agarose gel and transferred to Hybond-XL blotting membrane (GE Healthcare, Chicago, IL, USA, RPN20203) using standard alkaline transfer methods. The 5' and 3' external

probes were generated by PCR with primer sequences shown in **Supplementary file 4A**. Southern blot hybridization was conducted as described previously (Li *et al.*, 2011).

Northern blotting

10 µg of purified RNA was resolved by denaturing formaldehyde agarose gel electrophoresis with MOPS buffer. RNA was transferred to Hybond-XL membrane in 1xSSC buffer overnight by capillary transfer. RNA was UV cross-linked to the membrane and pre-hybridised with Expresshyb (Clontech, Mountainview, CA, USA, 636831) for 2 hr at 65°C. The DNA probe was generated by PCR (primers are shown in **Supplementary file 4B**) and 25 ng of probe DNA was labelled with [³²P]-dCTP using Radprime DNA labeling system (Thermo Fisher Scientific, 18428-011). The free-nucleotide was removed from labelled probe using G-50 column (GE Healthcare, 27-5330-01), and was heat-denatured followed by snap cooling. The probe was added to the pre-hybridised membrane and incubated overnight at 65°C in a rolling incubator. Membrane was washed with wash buffer containing 0.1 x SSC and 0.1% SDS 3 times at 65°C with 10 min intervals. The membrane was placed in a phosphorimager and exposed for at least overnight at -80°C before scanned using Typhoon 9410 phosphorimager system (GE Healthcare).

5' and 3' RACE

5' RACE was conducted using 5'-Full RACE Core Set (Takara, Kusatsu, Japan, #6122) following manufacturer's protocol. The sequences for RT-primer and nested PCR primers A1, A2, S1, and S2 are shown in **Supplementary file 5A**. 3' RACE was conducted by using a polyT RT-primer with a unique sequence tag to synthesis cDNA. The 3' end region was PCR amplified using a primer specific to the RT-primer and a gene specific primer. The primers are shown in **Supplementary file 5B**. Both 5' and 3' RACE PCR products were cloned into plasmids using Zero blunt TOPO PCR cloning kit (Thermo Fisher Scientific, 451245) for subsequent sequencing.

RNA extraction, reverse transcription and Real-time PCR

Total RNA was isolated using Trizol (Thermo Fisher Scientific, 15596026) or RNeasy kit (Qiagen, Hilden, Germany, 74136) and DNase treatment was conducted either after RNA purification or during column purification. cDNA was transcribed from 0.5 ~ 1 µg RNA using SuperScriptIII (Thermo Fisher Scientific, 18080044) and oligo-dT priming. Real-time PCR was performed using StepOnePlus machine (Applied Biosystems) with Fast Sybrgreen master mix (Thermo Fisher Scientific, 4385612). Target gene primer sequences are shown in **Supplementary file 6**. Expression level were normalised to Actinβ. Technical replicates for at least two independent experiments were conducted. The results were shown as mean and standard deviation calculated by StepOnePlus software (Applied Biosystems). The cDNA library for E7-E17 embryos and adult tissues were purchased from Clontech (Mouse Total RNA Master Panel, 636644).

RNA-FISH

RNA-FISH was conducted using ViewRNA ISH Cell Assay for Fluorescence RNA In Situ Hybridization system (Thermo Fisher Scientific, QVC0001) with modifications and imaged on a DeltaVision Core system (Applied Precision), as described in **Bergmann *et al.* (2015)**. The probe set used for *Epheron* was VX1-99999-01.

Mature miRNA expression profiling

Total RNA was extracted using Trizol. 1 µg RNA was reverse transcribed using Taqman MicroRNA Reverse Transcription Kit (Thermo Fisher Scientific, 366596). Mature miRNA expression was analysed using Taqman Array Rodent MicroRNA A + B Cared Set V3.0 (Thermo Fisher Scientific, 444909).

Luciferase assay

The Entire 3'UTR of both *Dnmt3a* and *Dnmt3b* were PCR cloned downstream of the firefly luciferase coding region into pGL3 vector. For *Dnmt3a* 3'UTR, forward primer AATTGGCCGGCCGGGACA TGGGGGCAAAGTGAAGTAG and reverse primer AATTGGATCCGGGAAGCCAAAACATAAAGATG TTTATTGAAGCTC were used for PCR cloning. For *Dnmt3b* 3'UTR, forward primer AA TTGGCCGGCCTTCTACCCAGGACTGGGGAGCTCTC and reverse primer AATTGGATCCTTA

TAGAGAAATACAACCTTAATCAACCAGAAAGG were used for PCR cloning. To generate mutant Dnmt3b reporter constructs, *let-7g* binding site was mutated to include BsrGI (mutation V1) and EcoRI (mutation V2) sites by PCR cloning. Each firefly luciferase construct (500 ng) together with Renilla luciferase construct (10 ng) were con-transfected with either *let-7g* mimic or scrambled control (20 nM). The firefly and Renilla luciferase activity was determined by dual luciferase assay (Promega, E1960) 48 hr post-transfection.

Immunostaining

Cells were fixed in 4% paraformaldehyde for 10 min at room temperature and were blocked with blocking buffer (5% semi-skimmed milk with 0.1% Triton in PBS) for 2 hr at room temperature. Primary antibodies were diluted in blocking buffer and incubated at 4°C overnight. Primary antibody was carefully washed away with 0.1% Triton in PBS three times with 10 min incubation between each wash. Secondary antibody diluted in blocking buffer (1:1000) was incubated at room temperature for 1 hr followed by 3 washes with 0.1% Triton in PBS. Nuclei were counterstained with DAPI. Primary antibodies used were Nanog (eBioscience, 14–5761, RRID:AB_763613, 1:200) and Lin28a (Cell signalling, 3978, RRID:AB_2297060, 1:800; 8706, RRID:AB_10896850, 1:200). Images from random fields were taken with Leica DMI3000 and the images from different fields at each time point were combined and analysed using CellProfiler software (Broad Institute, RRID:SCR_007358) to conduct nuclear and cytoplasmic compartmentalisation and total fluorescent intensity for each sub-cellular compartments as well as the whole cell for each cell was extracted for correlation analysis.

Chromatin isolation by RNA purification (ChIRP)

The antisense oligo probes were selected with GC content in the range of 40–50% in regions of the *Eprn* exons without repetitive sequences (**Figure 1—figure supplement 1A**). The probes sequences are in shown in **Supplementary file 7**. ChIRP was conducted following published protocol (**Chu et al., 2011**). The data is available at the NCBI Gene Expression Omnibus (accession number: GSE90574). The link to the data is as follows: <http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE90574>.

ChIP

The experimental procedure was conducted as described previously (**Betschinger et al., 2013**). 2 μ g of H3K4me3 antibody (Diagenode, Ougrée, Belgium pAb-003–050) and IgG control (Santa Cruz, Dallas, TX, USA, sc-2345) was used for 4×10^6 cells per ChIP. qPCR was performed with primers shown in **Supplementary file 8**.

Nanog promoter DNA methylation analysis

Genomic DNA was extracted using GenElute Mammalian Genomic DNA miniprep kit (Sigma Aldrich, G1N70-1KT). 500 ng purified genomic DNA was treated with sodium bisulfite to convert all unmethylated cytosine residues into uracil residues using Imprint DNA modification Kit (Sigma Aldrich, MOD50-1KT) according to the manufacturer's protocol. *Nanog* proximal promoter regions (Region 1 and 2 as indicated in **Figure 5a**) were amplified using a nested PCR approach with KAPA HiFi Uracil + Readymix (KapaBiosystems/Roche, Basel, Switzerland, KK2801). The PCR condition for both nested rounds of PCR is as follows: denaturation at 98°C for 5 min followed by 10 cycles of gradient PCR, 98°C for 15 s, 62°C (starting annealing temperature) for 15 s with annealing temperature reduced by 1°C per cycle and 72°C for 1.5 min. Followed by this, a 35 cycles of 98°C for 15 s, 58°C for 15 s and 72°C for 1.5 min were conducted. 2 μ l first round PCR product was used as template for the nested PCR. All primer sequences are shown in **Supplementary file 9**. The PCR products were verified and purified by gel electrophoresis and subsequently subcloned by TOPO cloning. Reconstructed plasmids were purified and individual clones were sequenced (Eurofins).

Transcriptome sequencing and analysis

Total RNA was isolated with RNeasy RNA purification. Ribo-zero rRNA depleted RNA was used to generate sequencing libraries for wild type and Ephemeron knockout cells in PD/LIF and 8 hr withdrawal from PDL from three independent cell lines. Single end sequencing was performed and the reads were mapped using NCBI38/mm10 with Ensembl version 75 annotations. RNA-seq reads were

aligned to the reference genome using tophat2. Only uniquely mapped reads were used for further analysis. Gene counts from SAM files were obtained using htseq-count with mode intersection non-empty, -s reverse. Differential gene expression analysis was conducted using Bioconductor R package DESeq2 version 1.4.5. DESeq2 provides two P-values, a raw P-value and a Benjamini-Hochberg P-value (adjusted p value). An adjusted p-Value threshold of 0.05 was used to determine differential gene expression (95% of the results are not false discoveries, error rate 0.05 = 5%). The data is available at the NCBI Gene Expression Omnibus (accession number: GSE90574, <https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE90574>).

Eprn promoter CpG methylation analysis

Using published genome-wide bisulphite sequencing data (Kalkan *et al.*, 2017; Seisenberger *et al.*, 2012; Wang *et al.*, 2014), *Eprn* promoter region was defined as the 2 kb region upstream of the TSS and the percentage of CpG methylation within the region was quantified. For promoter average, percentage of CpG methylation around the 2 kb promoter region of each annotated gene was quantified and averaged for all values. For genome average, percentage of CpG methylation of all 50 kb tiling windows was quantified and averaged all values.

Acknowledgements

We thank Kosuke Yusa and Graziano Martello for comments on the manuscript. We are grateful to Carla Mulas for assisting the miRNA expression plot, Yiping Zhang for lncRNA candidate prediction analysis and Rosalind Drummond for technical support. We thank Heather Lee for providing Dnmt3a and Dnmt3b siRNAs and Wolf Reik for support. We thank Nicholas Ingolia for useful discussion on lncRNA ribosomal footprinting. We also thank Peter Humphreys and Andy Riddell for technical support for imaging analysis and flow cytometry respectively. AS is supported by Medical Research Council (G1100526/1), Biotechnology and Biological Sciences Research Council (BB/M004023/1), European Commission (HEALTH-F4-2007-200720 EUROSYSYSTEM), and Wellcome Trust (091484/Z/10/Z). LH is supported by National Cancer Institute (R01 CA139067, 1R21CA175560-01) and California Institute of Regenerative Medicine (RN2-00923-1), American Cancer Society (123339-RSG-12-265-01-RMC), Tobacco-related Disease Research Program (21RT-0133). DLS is supported by NIGMS 42694 and NCI 5P01CA013106-Project 3. TK is supported by programme grants from Cancer Research UK (C6/A18796) and European Research Council CRIPTON Grant (268569) and core grants from the Wellcome Trust (092096) and Cancer Research UK (C6946/A14492). The Cambridge Stem Cell Institute receives core funding from the Wellcome Trust and the Medical Research Council. MAL was a Siebel postdoctoral fellow at the University of California, Berkeley and a Sir Henry Wellcome postdoctoral fellow (096125/Z/11/Z). AS is a Medical Research Council Professor.

Additional information

Funding

Funder	Grant reference number	Author
Wellcome	Sir Henry Wellcome Postdoctoral Fellowship	Meng Amy Li
California Institute for Regenerative Medicine	Research Grant	Lin He
Wellcome	Research Grant	Austin Smith
Medical Research Council	Research Grant	Austin Smith
National Institute of General Medical Sciences	Research Grant	David L Spector
National Cancer Institute	Research Grant	David L Spector Lin He
Cancer Research UK	Research Grant	Tony Kouzarides
European Research Council	Research Grant	Tony Kouzarides

Biotechnology and Biological Sciences Research Council	Research Grant	Austin Smith
European Commission	Research Grant	Austin Smith
American Cancer Society	Research Scholar Award	Lin He
Tobacco-Related Disease Research Program	Research Grant	Lin He

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Author contributions

MAL, Conceptualization, Data curation, Formal analysis, Funding acquisition, Validation, Investigation, Visualization, Methodology, Writing—original draft, Writing—review and editing; PPA, Formal analysis, Investigation, Methodology, Writing—review and editing; PC, MK, MP, JN, Investigation, Methodology; JHB, FvM, Formal analysis, Investigation, Methodology; TKa, Resources, Data curation; MR, Formal analysis, Visualization; SR, Data curation, Formal analysis, Visualization; FY, Formal analysis, Investigation; CC, Resources, Dr. Chen provided miRNA expression profiling assays; DLS, LH, Supervision, Funding acquisition, Writing—review and editing; TKo, Supervision, Funding acquisition; AS, Supervision, Funding acquisition, Writing—original draft, Writing—review and editing

Author ORCIDs

Meng Amy Li, <http://orcid.org/0000-0002-6619-9919>

Austin Smith, <http://orcid.org/0000-0002-3029-4682>

Additional files

Supplementary files

- Supplementary file 1. Primers for generating *Eprn* Targeting vector and genotyping.
DOI: [10.7554/eLife.23468.019](https://doi.org/10.7554/eLife.23468.019)
- Supplementary file 2. Primers for generating gRNAs vectors and genotyping for *Dnmt3a/3b* knockouts.
DOI: [10.7554/eLife.23468.020](https://doi.org/10.7554/eLife.23468.020)
- Supplementary file 3. siRNAs and mature miRNA mimics used in this study.
DOI: [10.7554/eLife.23468.021](https://doi.org/10.7554/eLife.23468.021)
- Supplementary file 4. Primers for generating Southern and Northern blotting probes by PCR.
DOI: [10.7554/eLife.23468.022](https://doi.org/10.7554/eLife.23468.022)
- Supplementary file 5. Primers for RACE and nested PCR amplification.
DOI: [10.7554/eLife.23468.023](https://doi.org/10.7554/eLife.23468.023)
- Supplementary file 6. Primers for Real-time quantitative RT-PCR.
DOI: [10.7554/eLife.23468.024](https://doi.org/10.7554/eLife.23468.024)
- Supplementary file 7. ChIRP probes used in this study.
DOI: [10.7554/eLife.23468.025](https://doi.org/10.7554/eLife.23468.025)
- Supplementary file 8. Primers used for *Lin28a* promoter ChIP PCR.
DOI: [10.7554/eLife.23468.026](https://doi.org/10.7554/eLife.23468.026)
- Supplementary file 9. Primers used for *Nanog* promoter DNA methylation analysis.
DOI: [10.7554/eLife.23468.027](https://doi.org/10.7554/eLife.23468.027)

Major datasets

The following dataset was generated:

Author(s)	Year	Dataset title	Dataset URL	Database, license, and accessibility information
Li MA, Amaral PP, Cheung P, Bergmann JH, Kinoshita M, Kalkan T, Ralser	2016	A lncRNA/Lin28/let7 axis coupled to DNA methylation fines tunes the dynamics of a cell state transition	http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE90574	Publicly available at the NCBI Gene Expression Omnibus (accession no: GSE90574)

M, Robson S,
Paramor M, Yang F,
Chen C, Nichols J,
Spector DL, Kou-
zarides T, He L,
Smith A

GSE90574)

References

- Acampora D**, Omodei D, Petrosino G, Garofalo A, Savarese M, Nigro V, Di Giovannantonio LG, Mercadante V, Simeone A. 2016. Loss of the Otx2-Binding site in the Nanog promoter affects the integrity of embryonic stem cell subtypes and specification of Inner cell mass-derived epiblast. *Cell Reports* **15**:2651–2664. doi: [10.1016/j.celrep.2016.05.041](https://doi.org/10.1016/j.celrep.2016.05.041), PMID: [27292645](https://pubmed.ncbi.nlm.nih.gov/27292645/)
- Auclair G**, Guibert S, Bender A, Weber M. 2014. Ontogeny of CpG island methylation and specificity of DNMT3 methyltransferases during embryonic development in the mouse. *Genome Biology* **15**:1–16. doi: [10.1186/s13059-014-0545-5](https://doi.org/10.1186/s13059-014-0545-5), PMID: [25476147](https://pubmed.ncbi.nlm.nih.gov/25476147/)
- Bergmann JH**, Li J, Eckersley-Maslin MA, Rigo F, Freier SM, Spector DL. 2015. Regulation of the ESC transcriptome by nuclear long noncoding RNAs. *Genome Research* **25**:1336–1346. doi: [10.1101/gr.189027.114](https://doi.org/10.1101/gr.189027.114), PMID: [26048247](https://pubmed.ncbi.nlm.nih.gov/26048247/)
- Betschinger J**, Nichols J, Dietmann S, Corrin PD, Paddison PJ, Smith A. 2013. Exit from pluripotency is gated by intracellular redistribution of the bHLH transcription factor Tfe3. *Cell* **153**:335–347. doi: [10.1016/j.cell.2013.03.012](https://doi.org/10.1016/j.cell.2013.03.012), PMID: [23582324](https://pubmed.ncbi.nlm.nih.gov/23582324/)
- Blakeley P**, Fogarty NM, del Valle I, Wamaitha SE, Hu TX, Elder K, Snell P, Christie L, Robson P, Niakan KK. 2015. Defining the three cell lineages of the human blastocyst by single-cell RNA-seq. *Development* **142**:3151–3165. doi: [10.1242/dev.123547](https://doi.org/10.1242/dev.123547), PMID: [26293300](https://pubmed.ncbi.nlm.nih.gov/26293300/)
- Boroviak T**, Loos R, Lombard P, Okahara J, Behr R, Sasaki E, Nichols J, Smith A, Bertone P. 2015. Lineage-Specific Profiling delineates the emergence and progression of naive pluripotency in mammalian embryogenesis. *Developmental Cell* **35**:366–382. doi: [10.1016/j.devcel.2015.10.011](https://doi.org/10.1016/j.devcel.2015.10.011), PMID: [26555056](https://pubmed.ncbi.nlm.nih.gov/26555056/)
- Bradley A**, Evans M, Kaufman MH, Robertson E. 1984. Formation of germ-line chimaeras from embryo-derived teratocarcinoma cell lines. *Nature* **309**:255–256. doi: [10.1038/309255a0](https://doi.org/10.1038/309255a0), PMID: [6717601](https://pubmed.ncbi.nlm.nih.gov/6717601/)
- Brons IG**, Smithers LE, Trotter MW, Rugg-Gunn P, Sun B, Chuva de Sousa Lopes SM, Howlett SK, Clarkson A, Ahrlund-Richter L, Pedersen RA, Vallier L. 2007. Derivation of pluripotent epiblast stem cells from mammalian embryos. *Nature* **448**:191–195. doi: [10.1038/nature05950](https://doi.org/10.1038/nature05950), PMID: [17597762](https://pubmed.ncbi.nlm.nih.gov/17597762/)
- Buecker C**, Srinivasan R, Wu Z, Calo E, Acampora D, Faial T, Simeone A, Tan M, Swigut T, Wysocka J. 2014. Reorganization of enhancer patterns in transition from naive to primed pluripotency. *Cell Stem Cell* **14**:838–853. doi: [10.1016/j.stem.2014.04.003](https://doi.org/10.1016/j.stem.2014.04.003), PMID: [24905168](https://pubmed.ncbi.nlm.nih.gov/24905168/)
- Carninci P**, Kasukawa T, Katayama S, Gough J, Frith MC, Maeda N, Oyama R, Ravasi T, Lenhard B, Wells C, Kodzius R, Shimokawa K, Bajic VB, Brenner SE, Batalov S, Forrest AR, Zavolan M, Davis MJ, Wilming LG, Aidinis V, et al. 2005. The transcriptional landscape of the mammalian genome. *Science* **309**:1559–1563. doi: [10.1126/science.1112014](https://doi.org/10.1126/science.1112014), PMID: [16141072](https://pubmed.ncbi.nlm.nih.gov/16141072/)
- Chambers I**, Silva J, Colby D, Nichols J, Nijmeijer B, Robertson M, Vrana J, Jones K, Grotewold L, Smith A. 2007. Nanog safeguards pluripotency and mediates germline development. *Nature* **450**:1230–1234. doi: [10.1038/nature06403](https://doi.org/10.1038/nature06403), PMID: [18097409](https://pubmed.ncbi.nlm.nih.gov/18097409/)
- Chen X**, Xu H, Yuan P, Fang F, Huss M, Vega VB, Wong E, Orlov YL, Zhang W, Jiang J, Loh YH, Yeo HC, Yeo ZX, Narang V, Govindarajan KR, Leong B, Shahab A, Ruan Y, Bourque G, Sung WK, et al. 2008. Integration of external signaling pathways with the core transcriptional network in embryonic stem cells. *Cell* **133**:1106–1117. doi: [10.1016/j.cell.2008.04.043](https://doi.org/10.1016/j.cell.2008.04.043), PMID: [18555785](https://pubmed.ncbi.nlm.nih.gov/18555785/)
- Cho J**, Chang H, Kwon SC, Kim B, Kim Y, Choe J, Ha M, Kim YK, Kim VN. 2012. LIN28A is a suppressor of ER-associated translation in embryonic stem cells. *Cell* **151**:765–777. doi: [10.1016/j.cell.2012.10.019](https://doi.org/10.1016/j.cell.2012.10.019), PMID: [23102813](https://pubmed.ncbi.nlm.nih.gov/23102813/)
- Chu C**, Qu K, Zhong FL, Artandi SE, Chang HY. 2011. Genomic maps of long noncoding RNA occupancy reveal principles of RNA-chromatin interactions. *Molecular Cell* **44**:667–678. doi: [10.1016/j.molcel.2011.08.027](https://doi.org/10.1016/j.molcel.2011.08.027), PMID: [21963238](https://pubmed.ncbi.nlm.nih.gov/21963238/)
- Davies OR**, Lin CY, Radzishewska A, Zhou X, Taube J, Blin G, Waterhouse A, Smith AJ, Lowell S. 2013. Tcf15 primes pluripotent cells for differentiation. *Cell Reports* **3**:472–484. doi: [10.1016/j.celrep.2013.01.017](https://doi.org/10.1016/j.celrep.2013.01.017), PMID: [23395635](https://pubmed.ncbi.nlm.nih.gov/23395635/)
- Dinger ME**, Amaral PP, Mercer TR, Pang KC, Bruce SJ, Gardiner BB, Askarian-Amiri ME, Ru K, Soldà G, Simons C, Sunkin SM, Crowe ML, Grimmond SM, Perkins AC, Mattick JS. 2008. Long noncoding RNAs in mouse embryonic stem cell pluripotency and differentiation. *Genome Research* **18**:1433–1445. doi: [10.1101/gr.078378.108](https://doi.org/10.1101/gr.078378.108), PMID: [18562676](https://pubmed.ncbi.nlm.nih.gov/18562676/)
- Dunn SJ**, Martello G, Yordanov B, Emmott S, Smith AG. 2014. Defining an essential transcription factor program for naïve pluripotency. *Science* **344**:1156–1160. doi: [10.1126/science.1248882](https://doi.org/10.1126/science.1248882), PMID: [24904165](https://pubmed.ncbi.nlm.nih.gov/24904165/)
- Durruthy-Durruthy J**, Sebastiano V, Wossidlo M, Cepeda D, Cui J, Grow EJ, Davila J, Mall M, Wong WH, Wysocka J, Au KF, Reijo Pera RA. 2016. The primate-specific noncoding RNA HPAT5 regulates pluripotency during human preimplantation development and nuclear reprogramming. *Nature Genetics* **48**:44–52. doi: [10.1038/ng.3449](https://doi.org/10.1038/ng.3449), PMID: [26595768](https://pubmed.ncbi.nlm.nih.gov/26595768/)

- Ebisuya M**, Yamamoto T, Nakajima M, Nishida E. 2008. Ripples from neighbouring transcription. *Nature Cell Biology* **10**:1106–1113. doi: [10.1038/ncb1771](https://doi.org/10.1038/ncb1771), PMID: [19160492](https://pubmed.ncbi.nlm.nih.gov/19160492/)
- Engreitz JM**, Haines JE, Perez EM, Munson G, Chen J, Kane M, McDonel PE, Guttman M, Lander ES. 2016. Local regulation of gene expression by lncRNA promoters, transcription and splicing. *Nature* **539**:452–455. doi: [10.1038/nature20149](https://doi.org/10.1038/nature20149), PMID: [27783602](https://pubmed.ncbi.nlm.nih.gov/27783602/)
- Evans MJ**, Kaufman MH. 1981. Establishment in culture of pluripotential cells from mouse embryos. *Nature* **292**:154–156. doi: [10.1038/292154a0](https://doi.org/10.1038/292154a0), PMID: [7242681](https://pubmed.ncbi.nlm.nih.gov/7242681/)
- Farthing CR**, Ficiz G, Ng RK, Chan CF, Andrews S, Dean W, Hemberger M, Reik W. 2008. Global mapping of DNA methylation in mouse promoters reveals epigenetic reprogramming of pluripotency genes. *PLoS Genetics* **4**:e1000116. doi: [10.1371/journal.pgen.1000116](https://doi.org/10.1371/journal.pgen.1000116), PMID: [18584034](https://pubmed.ncbi.nlm.nih.gov/18584034/)
- Ficz G**, Branco MR, Seisenberger S, Santos F, Krueger F, Hore TA, Marques CJ, Andrews S, Reik W. 2011. Dynamic regulation of 5-hydroxymethylcytosine in mouse ES cells and during differentiation. *Nature* **473**:398–402. doi: [10.1038/nature10008](https://doi.org/10.1038/nature10008), PMID: [21460836](https://pubmed.ncbi.nlm.nih.gov/21460836/)
- Fort A**, Hashimoto K, Yamada D, Salimullah M, Keya CA, Saxena A, Bonetti A, Voineagu I, Bertin N, Kratz A, Noro Y, Wong CH, de Hoon M, Andersson R, Sandelin A, Suzuki H, Wei CL, Koseki H, Hasegawa Y, Forrest AR, et al. 2014. Deep transcriptome profiling of mammalian stem cells supports a regulatory role for retrotransposons in pluripotency maintenance. *Nature Genetics* **46**:558–566. doi: [10.1038/ng.2965](https://doi.org/10.1038/ng.2965), PMID: [24777452](https://pubmed.ncbi.nlm.nih.gov/24777452/)
- Guo G**, Yang J, Nichols J, Hall JS, Eyres I, Mansfield W, Smith A. 2009. Klf4 reverts developmentally programmed restriction of ground state pluripotency. *Development* **136**:1063–1069. doi: [10.1242/dev.030957](https://doi.org/10.1242/dev.030957), PMID: [19224983](https://pubmed.ncbi.nlm.nih.gov/19224983/)
- Guo G**, von Meyenn F, Santos F, Chen Y, Reik W, Bertone P, Smith A, Nichols J. 2016. Naive pluripotent stem cells derived directly from isolated cells of the human inner cell mass. *Stem Cell Reports* **6**:437–446. doi: [10.1016/j.stemcr.2016.02.005](https://doi.org/10.1016/j.stemcr.2016.02.005), PMID: [26947977](https://pubmed.ncbi.nlm.nih.gov/26947977/)
- Guo G**, von Meyenn F, Rostovskaya M, Clarke J, Dietmann S, Baker D, Sahakyan A, Myers S, Bertone P, Reik W, Plath K, Smith A. 2017. Epigenetic resetting of human pluripotency. *Development* **144**:2748–2763. doi: [10.1242/dev.146811](https://doi.org/10.1242/dev.146811), PMID: [28765214](https://pubmed.ncbi.nlm.nih.gov/28765214/)
- Guttman M**, Amit I, Garber M, French C, Lin MF, Feldser D, Huarte M, Zuk O, Carey BW, Cassady JP, Cabili MN, Jaenisch R, Mikkelsen TS, Jacks T, Hacohen N, Bernstein BE, Kellis M, Regev A, Rinn JL, Lander ES. 2009. Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. *Nature* **458**:223–227. doi: [10.1038/nature07672](https://doi.org/10.1038/nature07672), PMID: [19182780](https://pubmed.ncbi.nlm.nih.gov/19182780/)
- Guttman M**, Donaghey J, Carey BW, Garber M, Grenier JK, Munson G, Young G, Lucas AB, Ach R, Bruhn L, Yang X, Amit I, Meissner A, Regev A, Rinn JL, Root DE, Lander ES. 2011. lincRNAs act in the circuitry controlling pluripotency and differentiation. *Nature* **477**:295–300. doi: [10.1038/nature10398](https://doi.org/10.1038/nature10398), PMID: [21874018](https://pubmed.ncbi.nlm.nih.gov/21874018/)
- Guttman M**, Russell P, Ingolia NT, Weissman JS, Lander ES. 2013. Ribosome profiling provides evidence that large noncoding RNAs do not encode proteins. *Cell* **154**:240–251. doi: [10.1016/j.cell.2013.06.009](https://doi.org/10.1016/j.cell.2013.06.009), PMID: [23810193](https://pubmed.ncbi.nlm.nih.gov/23810193/)
- Göke J**, Lu X, Chan YS, Ng HH, Ly LH, Sachs F, Szczerbinska I. 2015. Dynamic transcription of distinct classes of endogenous retroviral elements marks specific populations of early human embryonic cells. *Cell Stem Cell* **16**:135–141. doi: [10.1016/j.stem.2015.01.005](https://doi.org/10.1016/j.stem.2015.01.005), PMID: [25658370](https://pubmed.ncbi.nlm.nih.gov/25658370/)
- Habibi E**, Brinkman AB, Arand J, Kroeze LI, Kerstens HH, Matarese F, Lepikhov K, Gut M, Brun-Heath I, Hubner NC, Benedetti R, Altucci L, Jansen JH, Walter J, Gut IG, Marks H, Stunnenberg HG. 2013. Whole-genome bisulfite sequencing of two distinct interconvertible DNA methylomes of mouse embryonic stem cells. *Cell Stem Cell* **13**:360–369. doi: [10.1016/j.stem.2013.06.002](https://doi.org/10.1016/j.stem.2013.06.002), PMID: [23850244](https://pubmed.ncbi.nlm.nih.gov/23850244/)
- Ivanova N**, Dobrin R, Lu R, Kotenko I, Levorse J, DeCoste C, Schafer X, Lun Y, Lemischka IR. 2006. Dissecting self-renewal in stem cells with RNA interference. *Nature* **442**:533–538. doi: [10.1038/nature04915](https://doi.org/10.1038/nature04915), PMID: [16767105](https://pubmed.ncbi.nlm.nih.gov/16767105/)
- Jang S**, Choubey S, Furchtgott L, Zou LN, Doyle A, Menon V, Loew EB, Krostag AR, Martinez RA, Madisen L, Levi BP, Ramanathan S. 2017. Dynamics of embryonic stem cell differentiation inferred from single-cell transcriptomics show a series of transitions through discrete cell states. *eLife* **6**:e20487. doi: [10.7554/eLife.20487](https://doi.org/10.7554/eLife.20487), PMID: [28296635](https://pubmed.ncbi.nlm.nih.gov/28296635/)
- Kalkan T**, Smith A. 2014. Mapping the route from naive pluripotency to lineage specification. *Philosophical Transactions of the Royal Society B: Biological Sciences* **369**:20130540. doi: [10.1098/rstb.2013.0540](https://doi.org/10.1098/rstb.2013.0540), PMID: [25349449](https://pubmed.ncbi.nlm.nih.gov/25349449/)
- Kalkan T**, Olova N, Roode M, Mulas C, Lee HJ, Nett I, Marks H, Walker R, Stunnenberg HG, Lilley KS, Nichols J, Reik W, Bertone P, Smith A. 2017. Tracking the embryonic stem cell transition from ground state pluripotency. *Development* **144**:1221–1234. doi: [10.1242/dev.142711](https://doi.org/10.1242/dev.142711), PMID: [28174249](https://pubmed.ncbi.nlm.nih.gov/28174249/)
- Kelley D**, Rinn J. 2012. Transposable elements reveal a stem cell-specific class of long noncoding RNAs. *Genome Biology* **13**:R107. doi: [10.1186/gb-2012-13-11-r107](https://doi.org/10.1186/gb-2012-13-11-r107), PMID: [23181609](https://pubmed.ncbi.nlm.nih.gov/23181609/)
- Kolodziejczyk AA**, Kim JK, Tsang JC, Ilicic T, Henriksson J, Natarajan KN, Tuck AC, Gao X, Bühler M, Liu P, Marioni JC, Teichmann SA. 2015. Single cell RNA-Sequencing of pluripotent states unlocks modular transcriptional variation. *Cell Stem Cell* **17**:471–485. doi: [10.1016/j.stem.2015.09.011](https://doi.org/10.1016/j.stem.2015.09.011), PMID: [26431182](https://pubmed.ncbi.nlm.nih.gov/26431182/)
- Kumar RM**, Cahan P, Shalek AK, Satija R, DaleyKeyser A, Li H, Zhang J, Pardee K, Gennert D, Trombetta JJ, Ferrante TC, Regev A, Daley GO, Collins JJ. 2014. Deconstructing transcriptional heterogeneity in pluripotent stem cells. *Nature* **516**:56–61. doi: [10.1038/nature13920](https://doi.org/10.1038/nature13920), PMID: [25471879](https://pubmed.ncbi.nlm.nih.gov/25471879/)

- Lai F, Orom UA, Cesaroni M, Beringer M, Taatjes DJ, Blobel GA, Shiekhattar R. 2013. Activating RNAs associate with mediator to enhance chromatin architecture and transcription. *Nature* **494**:497–501. doi: [10.1038/nature11884](https://doi.org/10.1038/nature11884), PMID: [23417068](https://pubmed.ncbi.nlm.nih.gov/23417068/)
- Lee EC, Yu D, Martinez de Velasco J, Tessarollo L, Swing DA, Court DL, Jenkins NA, Copeland NG. 2001. A highly efficient escherichia coli-based chromosome engineering system adapted for recombinogenic targeting and subcloning of BAC DNA. *Genomics* **73**:56–65. doi: [10.1006/geno.2000.6451](https://doi.org/10.1006/geno.2000.6451), PMID: [11352566](https://pubmed.ncbi.nlm.nih.gov/11352566/)
- Lee JT. 2012. Epigenetic regulation by long noncoding RNAs. *Science* **338**:1435–1439. doi: [10.1126/science.1231776](https://doi.org/10.1126/science.1231776), PMID: [23239728](https://pubmed.ncbi.nlm.nih.gov/23239728/)
- Leeb M, Dietmann S, Paramor M, Niwa H, Smith A. 2014. Genetic exploration of the exit from self-renewal using haploid embryonic stem cells. *Cell Stem Cell* **14**:385–393. doi: [10.1016/j.stem.2013.12.008](https://doi.org/10.1016/j.stem.2013.12.008), PMID: [24412312](https://pubmed.ncbi.nlm.nih.gov/24412312/)
- Leitch HG, McEwen KR, Turp A, Encheva V, Carroll T, Grabole N, Mansfield W, Nashun B, Knezovich JG, Smith A, Surani MA, Hajkova P. 2013. Naive pluripotency is associated with global DNA hypomethylation. *Nature Structural & Molecular Biology* **20**:311–316. doi: [10.1038/nsmb.2510](https://doi.org/10.1038/nsmb.2510), PMID: [23416945](https://pubmed.ncbi.nlm.nih.gov/23416945/)
- Li MA, Turner DJ, Ning Z, Yusa K, Liang Q, Eckert S, Rad L, Fitzgerald TW, Craig NL, Bradley A. 2011. Mobilization of giant piggyBac transposons in the mouse genome. *Nucleic Acids Research* **39**:e148. doi: [10.1093/nar/gkr764](https://doi.org/10.1093/nar/gkr764), PMID: [21948799](https://pubmed.ncbi.nlm.nih.gov/21948799/)
- Lin N, Chang KY, Li Z, Gates K, Rana ZA, Dang J, Zhang D, Han T, Yang CS, Cunningham TJ, Head SR, Duester G, Dong PD, Rana TM. 2014. An evolutionarily conserved long noncoding RNA TUNA controls pluripotency and neural lineage commitment. *Molecular Cell* **53**:1005–1019. doi: [10.1016/j.molcel.2014.01.021](https://doi.org/10.1016/j.molcel.2014.01.021), PMID: [24530304](https://pubmed.ncbi.nlm.nih.gov/24530304/)
- Lu X, Sachs F, Ramsay L, Jacques PÉ, Göke J, Bourque G, Ng HH. 2014. The retrovirus HERVH is a long noncoding RNA required for human embryonic stem cell identity. *Nature Structural & Molecular Biology* **21**:423–425. doi: [10.1038/nsmb.2799](https://doi.org/10.1038/nsmb.2799), PMID: [24681886](https://pubmed.ncbi.nlm.nih.gov/24681886/)
- Luo S, Lu JY, Liu L, Yin Y, Chen C, Han X, Wu B, Xu R, Liu W, Yan P, Shao W, Lu Z, Li H, Na J, Tang F, Wang J, Zhang YE, Shen X. 2016. Divergent lncRNAs regulate Gene expression and lineage differentiation in pluripotent cells. *Cell Stem Cell* **18**:637–652. doi: [10.1016/j.stem.2016.01.024](https://doi.org/10.1016/j.stem.2016.01.024), PMID: [26996597](https://pubmed.ncbi.nlm.nih.gov/26996597/)
- Marks H, Kalkan T, Menafra R, Denissov S, Jones K, Hofemeister H, Nichols J, Kranz A, Stewart AF, Smith A, Stunnenberg HG. 2012. The transcriptional and epigenomic foundations of ground state pluripotency. *Cell* **149**:590–604. doi: [10.1016/j.cell.2012.03.026](https://doi.org/10.1016/j.cell.2012.03.026), PMID: [22541430](https://pubmed.ncbi.nlm.nih.gov/22541430/)
- Manson A, Levine SS, Cole MF, Frampton GM, Brambrink T, Johnstone S, Guenther MG, Johnston WK, Wernig M, Newman J, Calabrese JM, Dennis LM, Volkert TL, Gupta S, Love J, Hannett N, Sharp PA, Bartel DP, Jaenisch R, Young RA. 2008. Connecting microRNA genes to the core transcriptional regulatory circuitry of embryonic stem cells. *Cell* **134**:521–533. doi: [10.1016/j.cell.2008.07.020](https://doi.org/10.1016/j.cell.2008.07.020), PMID: [18692474](https://pubmed.ncbi.nlm.nih.gov/18692474/)
- Martello G, Sugimoto T, Diamanti E, Joshi A, Hannah R, Ohtsuka S, Göttgens B, Niwa H, Smith A. 2012. Esrrb is a pivotal target of the Gsk3/Tcf3 Axis regulating embryonic stem cell self-renewal. *Cell Stem Cell* **11**:491–504. doi: [10.1016/j.stem.2012.06.008](https://doi.org/10.1016/j.stem.2012.06.008), PMID: [23040478](https://pubmed.ncbi.nlm.nih.gov/23040478/)
- Martello G, Smith A. 2014. The nature of embryonic stem cells. *Annual Review of Cell and Developmental Biology* **30**:647–675. doi: [10.1146/annurev-cellbio-100913-013116](https://doi.org/10.1146/annurev-cellbio-100913-013116), PMID: [25288119](https://pubmed.ncbi.nlm.nih.gov/25288119/)
- Martens JA, Laprade L, Winston F. 2004. Intergenic transcription is required to repress the *Saccharomyces cerevisiae* SER3 gene. *Nature* **429**:571–574. doi: [10.1038/nature02538](https://doi.org/10.1038/nature02538), PMID: [15175754](https://pubmed.ncbi.nlm.nih.gov/15175754/)
- Martin GR. 1981. Isolation of a pluripotent cell line from early mouse embryos cultured in medium conditioned by teratocarcinoma stem cells. *PNAS* **78**:7634–7638. doi: [10.1073/pnas.78.12.7634](https://doi.org/10.1073/pnas.78.12.7634), PMID: [6950406](https://pubmed.ncbi.nlm.nih.gov/6950406/)
- Melton C, Judson RL, Blleloch R. 2010. Opposing microRNA families regulate self-renewal in mouse embryonic stem cells. *Nature* **463**:621–626. doi: [10.1038/nature08725](https://doi.org/10.1038/nature08725), PMID: [20054295](https://pubmed.ncbi.nlm.nih.gov/20054295/)
- Miranda KC, Huynh T, Tay Y, Ang YS, Tam WL, Thomson AM, Lim B, Rigoutsos I. 2006. A pattern-based method for the identification of MicroRNA binding sites and their corresponding heteroduplexes. *Cell* **126**:1203–1217. doi: [10.1016/j.cell.2006.07.031](https://doi.org/10.1016/j.cell.2006.07.031), PMID: [16990141](https://pubmed.ncbi.nlm.nih.gov/16990141/)
- Monk M, Boubelik M, Lehnert S. 1987. Temporal and regional changes in DNA methylation in the embryonic, extraembryonic and germ cell lineages during mouse embryo development. *Development* **99**:371–382. PMID: [3653008](https://pubmed.ncbi.nlm.nih.gov/3653008/)
- Mulas C, Kalkan T, Smith A. 2017. NODAL Secures Pluripotency upon Embryonic Stem Cell Progression from the Ground State. *Stem Cell Reports* **9**:77–91. doi: [10.1016/j.stemcr.2017.05.033](https://doi.org/10.1016/j.stemcr.2017.05.033), PMID: [28669603](https://pubmed.ncbi.nlm.nih.gov/28669603/)
- Nagano T, Mitchell JA, Sanz LA, Pauler FM, Ferguson-Smith AC, Feil R, Fraser P. 2008. The Air noncoding RNA epigenetically silences transcription by targeting G9a to chromatin. *Science* **322**:1717–1720. doi: [10.1126/science.1163802](https://doi.org/10.1126/science.1163802), PMID: [18988810](https://pubmed.ncbi.nlm.nih.gov/18988810/)
- Necsulea A, Soumillon M, Warnefors M, Liechti A, Daish T, Zeller U, Baker JC, Grützner F, Kaessmann H. 2014. The evolution of lncRNA repertoires and expression patterns in tetrapods. *Nature* **505**:635–640. doi: [10.1038/nature12943](https://doi.org/10.1038/nature12943), PMID: [24463510](https://pubmed.ncbi.nlm.nih.gov/24463510/)
- Nichols J, Smith A. 2009. Naive and primed pluripotent states. *Cell Stem Cell* **4**:487–492. doi: [10.1016/j.stem.2009.05.015](https://doi.org/10.1016/j.stem.2009.05.015), PMID: [19497275](https://pubmed.ncbi.nlm.nih.gov/19497275/)
- Niwa H, Miyazaki J, Smith AG. 2000. Quantitative expression of Oct-3/4 defines differentiation, dedifferentiation or self-renewal of ES cells. *Nature Genetics* **24**:372–376. doi: [10.1038/74199](https://doi.org/10.1038/74199), PMID: [10742100](https://pubmed.ncbi.nlm.nih.gov/10742100/)
- Ohnishi Y, Huber W, Tsumura A, Kang M, Xenopoulos P, Kurimoto K, Oleś AK, Araúzo-Bravo MJ, Saitou M, Hadjantonakis AK, Hiiragi T. 2014. Cell-to-cell expression variability followed by signal reinforcement progressively segregates early mouse lineages. *Nature Cell Biology* **16**:27–37. doi: [10.1038/ncb2881](https://doi.org/10.1038/ncb2881), PMID: [24292013](https://pubmed.ncbi.nlm.nih.gov/24292013/)

- Okano M**, Bell DW, Haber DA, Li E. 1999. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. *Cell* **99**:247–257. doi: [10.1016/S0092-8674\(00\)81656-6](https://doi.org/10.1016/S0092-8674(00)81656-6), PMID: [10555141](https://pubmed.ncbi.nlm.nih.gov/10555141/)
- Osorno R**, Tsakiridis A, Wong F, Cambray N, Economou C, Wilkie R, Blin G, Scotting PJ, Chambers I, Wilson V. 2012. The developmental dismantling of pluripotency is reversed by ectopic Oct4 expression. *Development* **139**:2288–2298. doi: [10.1242/dev.078071](https://doi.org/10.1242/dev.078071), PMID: [22669820](https://pubmed.ncbi.nlm.nih.gov/22669820/)
- Pandolfini L**, Luzi E, Bressan D, Ucciferri N, Bertacchi M, Brandi R, Rocchiccioli S, D'Onofrio M, Cremisi F. 2016. RISC-mediated control of selected chromatin regulators stabilizes ground state pluripotency of mouse embryonic stem cells. *Genome Biology* **17**:94. doi: [10.1186/s13059-016-0952-x](https://doi.org/10.1186/s13059-016-0952-x), PMID: [27154007](https://pubmed.ncbi.nlm.nih.gov/27154007/)
- Paralkar VR**, Mishra T, Luan J, Yao Y, Kossenkov AV, Anderson SM, Dunagin M, Pimkin M, Gore M, Sun D, Konuthula N, Raj A, An X, Mohandas N, Bodine DM, Hardison RC, Weiss MJ. 2014. Lineage and species-specific long noncoding RNAs during erythro-megakaryocytic development. *Blood* **123**:1927–1937. doi: [10.1182/blood-2013-12-544494](https://doi.org/10.1182/blood-2013-12-544494), PMID: [24497530](https://pubmed.ncbi.nlm.nih.gov/24497530/)
- Ran FA**, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F. 2013. Genome engineering using the CRISPR-Cas9 system. *Nature Protocols* **8**:2281–2308. doi: [10.1038/nprot.2013.143](https://doi.org/10.1038/nprot.2013.143), PMID: [24157548](https://pubmed.ncbi.nlm.nih.gov/24157548/)
- Rani N**, Nowakowski TJ, Zhou H, Godshalk SE, Lisi V, Kriegstein AR, Kosik KS. 2016. A primate lncRNA mediates notch signaling during neuronal development by sequestering miRNA. *Neuron* **90**:1174–1188. doi: [10.1016/j.neuron.2016.05.005](https://doi.org/10.1016/j.neuron.2016.05.005), PMID: [27263970](https://pubmed.ncbi.nlm.nih.gov/27263970/)
- Rinn J**, Guttman M. 2014. RNA function. RNA and dynamic nuclear organization. *Science* **345**:1240–1241. doi: [10.1126/science.1252966](https://doi.org/10.1126/science.1252966), PMID: [25214588](https://pubmed.ncbi.nlm.nih.gov/25214588/)
- Rossant J**, Tam PP. 2017. New Insights into early human development: lessons for stem cell derivation and differentiation. *Cell Stem Cell* **20**:18–28. doi: [10.1016/j.stem.2016.12.004](https://doi.org/10.1016/j.stem.2016.12.004), PMID: [28061351](https://pubmed.ncbi.nlm.nih.gov/28061351/)
- Sanford JP**, Clark HJ, Chapman VM, Rossant J. 1987. Differences in DNA methylation during oogenesis and spermatogenesis and their persistence during early embryogenesis in the mouse. *Genes & Development* **1**:1039–1046. doi: [10.1101/gad.1.10.1039](https://doi.org/10.1101/gad.1.10.1039), PMID: [3428592](https://pubmed.ncbi.nlm.nih.gov/3428592/)
- Savić N**, Bär D, Leone S, Frommel SC, Weber FA, Vollenweider E, Ferrari E, Ziegler U, Kaech A, Shakhova O, Cinelli P, Santoro R. 2014. lncRNA maturation to initiate heterochromatin formation in the nucleolus is required for exit from pluripotency in ESCs. *Cell Stem Cell* **15**:720–734. doi: [10.1016/j.stem.2014.10.005](https://doi.org/10.1016/j.stem.2014.10.005), PMID: [25479748](https://pubmed.ncbi.nlm.nih.gov/25479748/)
- Seisenberger S**, Andrews S, Krueger F, Arand J, Walter J, Santos F, Popp C, Thienpont B, Dean W, Reik W. 2012. The dynamics of genome-wide DNA methylation reprogramming in mouse primordial germ cells. *Molecular Cell* **48**:849–862. doi: [10.1016/j.molcel.2012.11.001](https://doi.org/10.1016/j.molcel.2012.11.001), PMID: [23219530](https://pubmed.ncbi.nlm.nih.gov/23219530/)
- Sheik Mohamed J**, Gaughwin PM, Lim B, Robson P, Lipovich L. 2010. Conserved long noncoding RNAs transcriptionally regulated by Oct4 and nanog modulate pluripotency in mouse embryonic stem cells. *RNA* **16**:324–337. doi: [10.1261/rna.1441510](https://doi.org/10.1261/rna.1441510), PMID: [20026622](https://pubmed.ncbi.nlm.nih.gov/20026622/)
- Shinoda G**, Shyh-Chang N, Soysa TY, Zhu H, Seligson MT, Shah SP, Abo-Sido N, Yabuuchi A, Hagan JP, Gregory RI, Asara JM, Cantley LC, Moss EG, Daley GQ. 2013. Fetal deficiency of lin28 programs life-long aberrations in growth and glucose metabolism. *Stem Cells* **31**:1563–1573. doi: [10.1002/stem.1423](https://doi.org/10.1002/stem.1423), PMID: [23666760](https://pubmed.ncbi.nlm.nih.gov/23666760/)
- Smith ZD**, Chan MM, Humm KC, Karnik R, Mekhoubad S, Regev A, Eggan K, Meissner A. 2014. DNA methylation dynamics of the human preimplantation embryo. *Nature* **511**:611–615. doi: [10.1038/nature13581](https://doi.org/10.1038/nature13581), PMID: [25079558](https://pubmed.ncbi.nlm.nih.gov/25079558/)
- Smith A**. 2017. Formative pluripotency: the executive phase in a developmental continuum. *Development* **144**:365–373. doi: [10.1242/dev.142679](https://doi.org/10.1242/dev.142679), PMID: [28143843](https://pubmed.ncbi.nlm.nih.gov/28143843/)
- Sumi T**, Oki S, Kitajima K, Meno C. 2013. Epiblast ground state is controlled by canonical wnt/ β -catenin signaling in the postimplantation mouse embryo and epiblast stem cells. *PLoS One* **8**:e63378. doi: [10.1371/journal.pone.0063378](https://doi.org/10.1371/journal.pone.0063378), PMID: [23691040](https://pubmed.ncbi.nlm.nih.gov/23691040/)
- Takashima Y**, Guo G, Loos R, Nichols J, Ficiz G, Krueger F, Oxley D, Santos F, Clarke J, Mansfield W, Reik W, Bertone P, Smith A. 2014. Resetting transcription factor control circuitry toward ground-state pluripotency in human. *Cell* **158**:1254–1269. doi: [10.1016/j.cell.2014.08.029](https://doi.org/10.1016/j.cell.2014.08.029), PMID: [25215486](https://pubmed.ncbi.nlm.nih.gov/25215486/)
- Tesar PJ**, Chenoweth JG, Brook FA, Davies TJ, Evans EP, Mack DL, Gardner RL, McKay RD. 2007. New cell lines from mouse epiblast share defining features with human embryonic stem cells. *Nature* **448**:196–199. doi: [10.1038/nature05972](https://doi.org/10.1038/nature05972), PMID: [17597760](https://pubmed.ncbi.nlm.nih.gov/17597760/)
- Theunissen TW**, Powell BE, Wang H, Mitalipova M, Faddah DA, Reddy J, Fan ZP, Maetzel D, Ganz K, Shi L, Lungjangwa T, Imsoonthornruksa S, Stelzer Y, Rangarajan S, D'Alessio A, Zhang J, Gao Q, Dawlaty MM, Young RA, Gray NS, et al. 2014. Systematic identification of culture conditions for induction and maintenance of naive human pluripotency. *Cell Stem Cell* **15**:471–487. doi: [10.1016/j.stem.2014.07.002](https://doi.org/10.1016/j.stem.2014.07.002), PMID: [25090446](https://pubmed.ncbi.nlm.nih.gov/25090446/)
- Theunissen TW**, Friedli M, He Y, Planet E, O'Neil RC, Markoulaki S, Pontis J, Wang H, Iouranova A, Imbeault M, Duc J, Cohen MA, Wert KJ, Castanon R, Zhang Z, Huang Y, Nery JR, Drotar J, Lungjangwa T, Trono D, et al. 2016. Molecular criteria for defining the naive human pluripotent state. *Cell Stem Cell* **19**:502–515. doi: [10.1016/j.stem.2016.06.011](https://doi.org/10.1016/j.stem.2016.06.011), PMID: [27424783](https://pubmed.ncbi.nlm.nih.gov/27424783/)
- Triboulet R**, Pirouz M, Gregory RI. 2015. A single Let-7 MicroRNA bypasses LIN28-Mediated repression. *Cell Reports* **13**:260–266. doi: [10.1016/j.celrep.2015.08.086](https://doi.org/10.1016/j.celrep.2015.08.086), PMID: [26440890](https://pubmed.ncbi.nlm.nih.gov/26440890/)
- Viswanathan SR**, Daley GQ, Gregory RI. 2008. Selective blockade of microRNA processing by Lin28. *Science* **320**:97–100. doi: [10.1126/science.1154040](https://doi.org/10.1126/science.1154040), PMID: [18292307](https://pubmed.ncbi.nlm.nih.gov/18292307/)
- Wang L**, Zhang J, Duan J, Gao X, Zhu W, Lu X, Yang L, Zhang J, Li G, Ci W, Li W, Zhou Q, Aluru N, Tang F, He C, Huang X, Liu J. 2014. Programming and inheritance of parental DNA methylomes in mammals. *Cell* **157**:979–991. doi: [10.1016/j.cell.2014.04.017](https://doi.org/10.1016/j.cell.2014.04.017), PMID: [24813617](https://pubmed.ncbi.nlm.nih.gov/24813617/)

- Wray J**, Kalkan T, Gomez-Lopez S, Eckardt D, Cook A, Kemler R, Smith A. 2011. Inhibition of glycogen synthase kinase-3 alleviates Tcf3 repression of the pluripotency network and increases embryonic stem cell resistance to differentiation. *Nature Cell Biology* **13**:838–845. doi: [10.1038/ncb2267](https://doi.org/10.1038/ncb2267), PMID: [21685889](https://pubmed.ncbi.nlm.nih.gov/21685889/)
- Yang J**, van Oosten AL, Theunissen TW, Guo G, Silva JC, Smith A. 2010. Stat3 activation is limiting for reprogramming to ground state pluripotency. *Cell Stem Cell* **7**:319–328. doi: [10.1016/j.stem.2010.06.022](https://doi.org/10.1016/j.stem.2010.06.022), PMID: [20804969](https://pubmed.ncbi.nlm.nih.gov/20804969/)
- Ying QL**, Wray J, Nichols J, Batlle-Morera L, Doble B, Woodgett J, Cohen P, Smith A. 2008. The ground state of embryonic stem cell self-renewal. *Nature* **453**:519–523. doi: [10.1038/nature06968](https://doi.org/10.1038/nature06968), PMID: [18497825](https://pubmed.ncbi.nlm.nih.gov/18497825/)
- Young RA**. 2011. Control of the embryonic stem cell state. *Cell* **144**:940–954. doi: [10.1016/j.cell.2011.01.032](https://doi.org/10.1016/j.cell.2011.01.032), PMID: [21414485](https://pubmed.ncbi.nlm.nih.gov/21414485/)
- Yu J**, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, Nie J, Jonsdottir GA, Ruotti V, Stewart R, Slukvin II, Thomson JA. 2007. Induced pluripotent stem cell lines derived from human somatic cells. *Science* **318**:1917–1920. doi: [10.1126/science.1151526](https://doi.org/10.1126/science.1151526), PMID: [18029452](https://pubmed.ncbi.nlm.nih.gov/18029452/)
- Zhang J**, Ratanasirinrawoot S, Chandrasekaran S, Wu Z, Ficarro SB, Yu C, Ross CA, Cacchiarelli D, Xia Q, Seligson M, Shinoda G, Xie W, Cahan P, Wang L, Ng SC, Tintara S, Trapnell C, Onder T, Loh YH, Mikkelsen T, et al. 2016. LIN28 regulates stem cell metabolism and conversion to Primed Pluripotency. *Cell Stem Cell* **19**:66–80. doi: [10.1016/j.stem.2016.05.009](https://doi.org/10.1016/j.stem.2016.05.009), PMID: [27320042](https://pubmed.ncbi.nlm.nih.gov/27320042/)